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Non-steroidal anti-inflammatory drugs 
and paracetamol are commonly used 
analgesics in acute pain management. In 
the present study the permeation of these 
drugs into the central nervous system 
was evaluated in 160 healthy children.  
Diclofenac, ibuprofen, indomethacin and 
ketorolac permeated the cerebrospinal 
fluid readily and reached the highest 
concentrations one hour after intravenous 
dosing. However, the concentrations were 
100-fold lower when compared to that in 
plasma. Paracetamol performed different-
ly: the cerebrospinal fluid concentrations 
reached the level of plasma concentrations 
at one hour.  These results suggest that the 
optimal timing for intravenous adminis-
tration of non-opioid analgesics is an hour 
before the onset of acute pain.
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ABSTRACT 
Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol are widely used analgesics, 
acting in both the peripheral tissues and the central nervous system (CNS). However, knowledge 
on CNS permeation of these drugs in children in sparse. Therefore cerebrospinal fluid (CSF) 
penetration of diclofenac, ibuprofen, indomethacin, ketorolac, and paracetamol was studied in 
160 healthy children (aged 3 months to 12 years) undergoing surgery with spinal anaesthesia. A 
single intravenous bolus dose of the study drug was given 10 minutes – 5 hours preoperatively, 
and a CSF sample was obtained during lumbar puncture for spinal anaesthesia. The 
concentration of drug in the CSF and in a paired plasma sample was determined by a gas 
chromatography-mass spectrometry method and by fluorescence polarization immunoassay. 
After diclofenac 1 mg/kg, ibuprofen 10 mg/kg, indomethacin 0.35 mg/kg and ketorolac 0.5 mg/kg, 
the CSF concentrations ranged between 0.1 and 4.7 µg/l, 15 and 541 µg/l, 0.2 and 5.0 µg/l and 0.2 
and 3.0 µg/l, respectively. The concentration ratios CSF/plasma were below 0.05, because of high 
(>99%) protein binding in plasma. The highest CSF concentrations of diclofenac, ibuprofen and 
ketorolac were detected an 1 hour after the injection, but indomethacin performed differently, 
with the highest concentrations in the CSF observed earlier (<30 min).  
After paracetamol 15 mg/kg, the CSF concentrations ranged between 1.3 and 18.0 mg/l, with the 
highest concentrations at 1-2 hours. Paracetamol concentrations in the CSF reached and remained 
above the plasma concentrations after the first hour, because of low (<50%) protein binding of 
paracetamol in plasma.  
In conclusion, indomethacin, ibuprofen, diclofenac, ketorolac and paracetamol permeate readily 
into the CSF in children. The peak concentrations after intravenous dosing are observed within 
an hour. However, there are differences between the drugs in both the timing of peak CSF 
concentrations and CSF/plasma ratios. These differences could impact on the speed of onset of 
analgesia and the toxicity profile of individual drugs.  
National Library of Medicine (NLM) Classification: QV 38, QV 95, WL 203 
Medical Subject Headings (Mesh): Acetaminophen; Central Nervous System/drug effects; Cerebrospinal 
Fluid/drug effects; Child; Child, Preschool; Diclofenac; Dose-Response Relationship, Drug; Ibuprofen; 
Indomethacin; Infant; Ketorolac; Pharmacokinetics, Time Factors; Tissue Distribution 
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TIIVISTELMÄ 
Tulehduskipulääkkeet ja parasetamoli ovat yleisesti käytettyjä kipulääkkeitä. Niiden vaikutus 
tapahtuu sekä perifeerisissä kudoksissa että keskushermostossa. Näiden lääkkeiden 
kulkeutuminen lasten keskushermostoon tunnetaan huonosti. Tässä tutkimuksessa selvitettiin 
diklofenaakin, indometasiinin, ibuprofeenin, ketorolaakin ja parasetamolin kulkeutumista aivo-
selkäydinnesteeseen 160 terveellä lapsella (3 kk – 12 v), joille tehtiin leikkaus 
spinaalipuudutuksessa. Ennen puudutuksen pistämistä lapsille annettiin laskimoon yksi annos 
kipulääkettä. Spinaalipuudutuksen piston yhteydessä (10min – 5 tuntia lääkkeen annosta) otettiin 
aivo-selkäydinnestenäyte ja laskimoverinäyte. Näytteistä määritettiin lääkeainepitoisuus 
kaasukromatografia-massaspektrometria-menetelmällä ja fluoresenssi-polarisaatio-
immuunimääritys-menetelmällä (parasetamoli-pitoisuus). 
Diklofenaakin 1 mg/kg, indometasiinin 0,35 mg/kg, ibuprofeenin 10 mg/kg ja ketorolaakin 0,5 
mg/kg antamisen jälkeen, aivo-selkäydinnesteen lääkeainepitoisuus vaihteli väleillä 0,1 – 4,7 µg/l, 
15 – 541 µg/l, 0,2 – 5,0 µg/l ja 0,2 – 3,0 µg/l. Lääkeainepitoisuuksien aivo-selkäydinneste/plasma 
suhde oli alle 0.05, joka selittyy sillä, että plasmassa nämä lääkkeet sitoutuvat merkittävästi (>99 
%) proteiineihin. Diklofenaakin, ibuprofeenin ja ketorolaakin korkeimmat pitoisuudet aivo-
selkäydinnesteessä havaittiin tunnin kuluttua lääkkeen annosta, mutta korkeita 
indometasiinipitoisuuksia mitattiin aiemmin (<30 min). 
Parasetamolin 15 mg/kg antamisen jälkeen, lääkeainepitoisuus aivo-selkäydinnesteessä oli 1,3-
18,0 mg/l, ja korkeimmat pitoisuuden havaittiin tunnin kuluttua lääkkeen annosta. Parasetamolin 
pitoisuus aivo-selkäydinnesteessä saavutti saman tason kuin plasmassa tunnin kuluttua lääkkeen 
annosta, jonka jälkeen pitoisuudet aivo-selkäydinnesteessä ja plasmassa olivat samaa tasoa. Tämä 
selittyy parasetamolin vähäisellä (<50 %) sitoutumisella plasman proteiineihin. 
Tässä tutkimuksessa todettiin, että indometasiini, ibuprofeeni, diklofenaakki, ketorolaakki ja 
parasetamoli kulkeutuvat keskushermostoon lapsilla, ja korkeimmat lääkeainepitoisuudet 
aivoselkäydinnesteessä havaittiin tunnin kuluttua laskimoannostelun jälkeen. 
Huippupitoisuuden ajankohdassa ja aivo-selkäydinneste/plasma pitoisuuksien suhteissa 
havaittiin kuitenkin merkittäviä eroja lääkeaineiden välillä, jotka voivat selittää erot eri 
lääkeaineiden vaikutuksen alkamisessa ja haittavaikutuksissa.  
Luokitus: QV 38, QV 95, WL 203 
Yleinen suomalainen asiasanasto (YSA): aivo-selkäydinneste, farmakokinetiikka, ibuprofeeni, 
indometasiini, keskushermosto, lapset, lääkeaineet – pitoisuus, parasetamoli, tulehduskipulääkkeet 
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1 Introduction 
Every year 5-10% of children undergo anaesthesia and surgery in Europe. 
Orthopaedic, gastrointestinal and oto-rhino-laryngological procedures are the 
most common operations in children (Clergue et al. 1999). Surgical 
procedures, anaesthesia and postoperative pain have a significant impact on 
the well-being of children (Hermann et al. 2006, Jones et al. 2009, Wollgarten-
Hadamek et al. 2009). Postoperative pain in children is commonly managed 
with a multi-modal approach using paracetamol (acetaminophen), non-
steroidal anti-inflammatory drugs (NSAIDs), opioids, and local anaesthetics 
(Kraemer and Rose 2009). 
 
NSAIDs are used in infants and children older than 3 months to reduce pain, 
fever and inflammation, and in neonates to close the patent ductus arteriosus 
(PDA). They are commonly used for postoperative pain, because they reduce 
the need for opioids and increase patient satisfaction (Kokki 2003, Eustace and 
O'Hare 2007). However, NSAIDs may cause adverse effects, including gastric, 
renal and central nervous system (CNS) complications. Nevertheless, severe 
adverse effects are rare in short-term postoperative use in children. NSAIDs 
reduce pain by inhibiting the cyclooxygenase enzyme, both in the peripheral 
tissues and in the CNS. 
 
Paracetamol is used in neonates and older children to reduce pain and fever, 
and it is important that the dose is large enough, especially in postoperative 
pain management (Anderson et al. 2001). In clinical use, adverse effects of 
paracetamol are rare, but unintentional high doses may cause liver toxicity. 
The actions of paracetamol seem to be mediated mainly in the CNS.  
 
In order to have beneficial actions in the CNS, NSAIDs and paracetamol 
should permeate the CNS and achieve sufficient concentrations there to have 
an inhibitory effect on the central prostaglandin H2 synthetase (PGHS) 
enzyme, through which analgesic activity is mediated. However, the blood-
brain barrier (BBB) regulates drug permeation in the CNS. The physico-
chemical and pharmacokinetic characteristics of drugs have an effect on BBB 
permeation. The small molecular size and lipophilicity of NSAIDs and 
2 
paracetamol suggest that they may cross the BBB readily by diffusion (Davson 
and Segal 1996). However, extensive protein binding and ionization of 
NSAIDs may limit the amount of unbound drug available for permeation 
(Parepally 2005). 
 
There are some adult studies on CSF permeation of NSAIDs and paracetamol 
(Bannwarth et al. 1990, Bannwarth et al. 1992, Rice et al. 1993, Bannwarth et al. 
1995), but few paediatric studies. Ketoprofen has been studied in children 
with non-disturbed BBB (Kokki et al. 2002, Mannila et al. 2006), and 
paracetamol in children with intracranial pathologies (Anderson et al. 1998, 
van der Marel et al. 2003a). There are no previous studies of CSF permeation 
of indomethacin, ibuprofen, ketorolac, diclofenac and paracetamol in healthy 
children with a normal BBB. Therefore, this study was designed to evaluate 
the CSF permeation of indomethacin, ibuprofen, ketorolac, diclofenac and 
paracetamol in healthy infants and children aged 3 months to 12 years. An 
understanding of CSF pharmacokinetics in healthy children may help to 
understand both the onset time of analgesia and the toxicity profile of 
individual drugs. 
3 
2 Review of the literature 
2.1 NSAIDS AND PARACETAMOL 
 
2.1.1 History 
 
The medical use of willow tree leaves and extracts, containing salicylate, dates 
back to 3000 BC. Willow was used to treat pain, fever and inflammation by the 
Assyrians, Babylonians and Egyptians (Mahdi et al. 2006). Acetylsalicylic acid 
(aspirin) was synthesised by Felix Hoffmann in 1897 and marketed by Bayer 
in 1900 (Mahdi et al. 2006). Paracetamol was synthesized in 1878, and 
marketed in the 1950s to replace phenacetin (Bertolini et al. 2006). Numerous 
new NSAIDs, such as indomethacin, ibuprofen and diclofenac, were prepared 
in the 1960s, and marketed shortly thereafter (O’Neil et al. 2001). 
 
The mechanism of action of NSAIDs was discovered by Sir John Vane in 1971 
(Vane 1971). After characterizing the different roles of housekeeping 
prostaglandin H2 synthetase-1 (PGHS-1, cyclooxygenase-1, COX-1) and 
inducible PGHS-2 (COX-2), there was an enormous commercial interest in the 
development of COX-2-selective agents, coxibs. Coxibs became popular 
because of their better gastrointestinal safety, but their use decreased after 
2000 due to concerns about their cardiovascular safety (Helin-Salmivaara et al. 
2006). Sometimes paracetamol is considered to belong to the group of 
NSAIDs. However, paracetamol has a different mechanism of action 
Anderson 2008), and it is often classified in a group of other analgesics and 
antipyretics. 
 
2.1.2 Prevalence of use 
 
NSAIDs and paracetamol are the most commonly used drugs worldwide. In 
Finland, the prevalence of over-the-counter (OTC) analgesic use among 
children aged 0-12 years is 7% (Ylinen 2008), which is only a little less than 
that in adults (Turunen et al. 2005). In children, the most commonly used OTC 
analgesic is paracetamol (Ylinen 2008), whereas ibuprofen is the most common 
analgesic in adults (NAM, Finnish Statistics on Medicines 01/2009-06/2009). In 
4 
Finland, paracetamol, naproxen and ibuprofen are the most commonly 
prescribed analgesics in children (Närhi and Kokki 2003).  
 
In 2008, the pharmacy sales for NSAIDs were 86 DDD/1000 inhabitants/day, 
and for paracetamol 21 DDD/1000 inhabitants/day in Finland (NAM, Drug 
Consumption in 2005-2008). The use of NSAIDs increased 69 % during 1990-
2007 and the use of paracetamol increased nine-fold during 1990-2007 (NAM, 
Finnish Statistics on Medicines 1990-2007). The use of NSAIDs and 
paracetamol has also increased in children (Närhi and Kokki 2003). In 2009, 
the use of NSAIDs remained the same, and paracetamol use has rose by 9% 
compared with the previous year (NAM, Finnish Statistics on Medicines 
01/2009-06/2009).  
 
 
2.2 MODE OF ANALGESIC ACTION OF NSAIDS 
 
2.2.1 Prostaglandin H2 synthetase (PGHS) enzyme  
 
In 1971 Sir John Vane discovered that the inhibition of prostaglandin (PG) 
synthesis is the mechanism of action for aspirin and other NSAIDs (Vane 
1971). PGHS is the enzyme responsible for the metabolism of arachidonic acid 
to the unstable PGH2. The enzyme consists of two sites: a cyclooxygenase 
(COX) site and a peroxide (POX) site, which catalyse two reactions - a 
cyclooxygenase reaction in which arachidonic acid is converted to PGG2, and 
a peroxidase reaction in which PGG2 is converted to PGH2. PGH2 is further 
transformed by different prostaglandin synthetases to PGs (PGE2, PGD2, 
PGF2R, PGI2) and thromboxane A2 (TxA2) (Figure 1). PGs activate different 
G-protein coupled prostanoid-receptors, which affect cyclic adenosine 
monophosphate (cAMP), protein kinase c (PKC) and intracellular calcium, 
potassium and sodium concentrations (Svensson and Yaksh 2002, Tsuboi et al. 
2002). 
 
Two isoforms of the PGHS have been characterized. PGHS-1 (COX-1) and 
PGHS-2 (COX-2) are 60% homologous enzymes, but are coded by different 
genes in different chromosomes (loci 9q32-33.3 and 1q25.2-25.3, respectively). 
PGHS-1 is regarded as a housekeeping enzyme, acting constitutively in almost 
all cells and producing PGs that regulate physiological functions. PGHS-2 is 
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considered to be an inducible enzyme related to inflammation and 
pathological conditions, expressed in response to cytokines, mitogens, 
endotoxins and tumor promoters (Tanabe and Tohnai 2002, Blobaum and 
Marnett 2007). However, this seems to be too simple a viewpoint, since PGHS-
2 is physiologically expressed in the brain, kidneys and reproductive tissues 
(Patrignani et al. 2005), and PGHS-1 expression increases in response to 
surgery (Zhu et al. 2003). 
 
2.2.2 COX selectivity 
 
Aspirin binds covalently to the COX site of the PGHS enzyme, whereas other 
NSAIDs are competitive COX inhibitors. Different NSAIDs have different 
affinity to COX-1 and COX-2. Some NSAIDs (for example, indomethacin and 
ibuprofen) are relatively unselective as they inhibit both COX-1 and COX-2 at 
similar concentrations; and the newest NSAIDs (coxibs; for example, 
celecoxib) are COX-2 selective, as they inhibit COX-2 in lower concentrations 
than COX-1. The selectivity of NSAIDs is expressed as a ratio of inhibitory 
concentration 50% (IC50) for COX-1 and IC50 COX-2. IC50 is defined as the 
concentration of a drug, which is required for 50% inhibition of the enzyme or 
process. The selectivity of different compounds has been variable in different 
studies, since assays have different substrate concentrations, incubation times 
and protein concentration, and they may contain total cells, broken cells or 
enzymes from different species. Human whole blood assay is nowadays 
considered a standard (Tables 1-2) (Mitchell et al. 1993, Cryer and Feldman 
1998, Warner et al. 1999). 
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Figure 1. The arachidonic acid cascade, redrawn and modified from Vane et 
al. (1998) 
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Table 1. COX-selectivity of the analgesics investigated 
 
 IC50 COX-2/1 
human whole 
blood assay* 
IC80 COX-2/1 
human whole 
blood assay* 
IC50 COX-2/1 
cultured, 
intact bovine 
aortic 
endothelial 
cells¤ 
IC50 COX-2/1 
human whole 
blood assay° 
Indomethacin 80 11 60 1.78 
Ibuprofen 0.9 1.2 15 1.69 
Ketorolac 453 1176 - 0.68 
Diclofenac 0.5 0.27 0.7 0.05 
Paracetamol - - 7.4 + 0.25 
+ IC30 ratio 
* (Warner et al. 1999) ¤ (Mitchell et al. 1993) ° (Cryer and Feldman 1998) 
 
 
 
 
Table 2. IC50 (µg/l) in different study settings, of the analgesics investigated 
 
 human whole blood 
assay 
human monocytes cultured, intact 
bovine aortic 
endothelial cells 
 COX-1* COX-2* COX-1° COX-2° COX-1¤ COX-2¤ 
Indomethacin 4.7 358 3.2 110 10 600 
Ibuprofen 1 600 1 500 2 500 16 000 1 000 15 000 
Ketorolac 0.048 22 - - - - 
Diclofenac 22 11 22 7.7 500 350 
Paracetamol >15 000 7 400 - - 2 700 + 20 000 + 
+ IC30 ratio 
* (Warner et al. 1999), ° (Kato et al. 2001) and ¤ (Mitchell et al. 1993) 
8 
2.2.3 Peripheral site of action 
 
Traditionally, NSAIDs are considered to be peripherally acting analgesics, 
because i) NSAIDs reduce PG synthesis, ii) peripheral tissue PG 
concentrations rise following trauma and inflammation, and iii) peripherally 
injected PGs increase vascular permeability and sensitize peripheral 
nociceptors, resulting in oedema, allodynia and hyperalgesia (Ebersberger et 
al. 1999). As further evidence for the peripheral site of action, topically applied 
NSAIDs have been shown to be effective, although inferior to systemic 
NSAIDs, in some osteoarthritis (Lin et al. 2004), soft tissue injury (Galer et al. 
2000, Whitefield et al. 2002) and postoperative pain studies (Alessandri et al. 
2006). It seems that percutaneous formulations reduce PG concentrations in 
inflamed tissues with minimal systemic exposition. In low pH-induced 
cutaneous pain, ibuprofen gel analgesia was not inferior to systemic 
ibuprofen. Ibuprofen concentrations at the peripheral injury site were similar, 
although ibuprofen plasma concentrations were 62 ng/ml and 25 µg/ml, after 
cutaneous gel and systemic drug, respectively (Steen et al. 2000). Moreover, 
there is evidence for a clinically relevant peripheral analgesic action of intra-
articular NSAIDs in postoperative pain (Rømsing et al. 2000). 
 
2.2.4 Central site of action 
 
In addition to peripheral mechanisms, NSAIDs  also have a central site of 
action, confirmed in numerous rodent studies. After intrathecal NSAID 
injection near the spinal cord, reduced pain-related behaviour is observed, 
dose-dependently and synergistically with morphine. Moreover, PGHS-1 and 
PGHS-2 –enzymes are found constitutively in the spinal cord, dorsal root 
ganglia and spinal dorsal and ventral grey matter; CSF prostanoid 
concentrations rise in response to peripheral injury or inflammation; and 
intrathecal prostanoid injections evoke hyperalgesia (Svensson and Yaksh 
2002). 
 
The central component has been estimated to account for 40% of the total 
analgesic efficacy for diclofenac (Burian et al. 2003), and has been suggested to 
be more sensitive than the peripheral site of action for ketorolac (Gordon et al. 
2002). Moreover, it seems that spinal PGHS-1 and PGHS-2 have different roles 
in different pain states. It seems that spinal PGHS-2 is more involved in 
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inflammatory pain, whereas spinal PGHS-1 is more involved in the initial 
nociceptive pain (Zhu et al. 2003). 
 
2.2.5 Inflammatory pain 
 
Several studies confirm the role of spinal PGHS-2 in inflammatory pain. 
Firstly, the amount of spinal PGHS-2 and PGE2 increases in inflammatory 
pain. Secondly, this PGE2 release is blocked by intrathecal and systemic, 
selective COX-2 and unselective COX-inhibitors. Thirdly, the antihyperalgesic, 
dose-dependent, stereospescific effects of intrathecal COX-2 inhibitors, but not 
COX-1 inhibitors in inflammatory pain models have been proved. Fourthly, 
the antinociceptive activity (half maximal effective dose, ED50) of several 
intrathecal COX inhibitors is correlated to their in vitro potency in blocking 
COX-2 (IC50). Fifthly, drugs given by a spinal route are 100-500 times more 
potent than when given systemically (Malmberg and Yaksh 1992, Svensson 
and Yaksh 2002). It seems that PGE2-receptor EP2 subtype is the key mediator 
in spinal hyperalgesia followed by peripheral inflammation, but other PG 
receptors are involved in hyperalgesia after peripheral nerve injury and 
formalin injection (Reinold et al. 2005, Hösl et al. 2006). In rats after formalin 
injection, according to an experimental pain model protocol, the 
antinociceptive potency of intrathecal versus systemic (intraperitoneal) 
NSAIDs has been evaluated by Malmberg and Yaksh (1992) and Björkman 
(1995) (Table 3).  
 
2.2.6 Nociceptive pain 
 
Spinal PGHS-1 seems to play a major role in postoperative pain. In rats after 
paw surgery, PGHS-1 expression increases in the ipsilateral L4-L6 spinal 
dorsal horn, especially in the medial part, and in the gracile nucleus. In rats, 
intrathecally administered COX-1 inhibitors, but not COX-2 inhibitors, 
effectively reduce mechanical hypersensitivity after paw surgery (Zhu et al. 
2003, Zhu et al. 2005) and restore normal behaviour after laparotomy (Martin 
et al. 2006).  
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Table 3. Half maximal effective doses (ED50) of intrathecal and systemic 
analgesics in animal models of inflammatory pain 
 
 ED50 (μg) Potency ratio 
ip vs it  it ip 
Indomethacin * 0.68 930 807 
S(+) Ibuprofen * 3.2 NT NT 
R (-) Ibuprofen * >56 NT NT 
Racemic ibuprofen * 3.9 NT NT 
Ketorolac * 1.3 770 216 
Diclofenac ¤ 3 300 100 
Acetaminophen * 39 910 23 
it intrathecal 
ip intraperitoneal 
NT not tested 
* rat formalin test (Malmberg and Yaksh 1992)  ¤ rat writhing test (Björkman 
1995) 
 
 
 
2.2.7 Intrathecal administration 
 
In rats, intrathecal COX-1 inhibitors perform well in postoperative pain with 
minimal systemic exposure. Therefore, the desire to administer NSAIDs 
intrathecally to humans has arisen. The safety and efficacy of intrathecal 
ketorolac infusion has been studied in dogs and rats (Yaksh et al. 2004). Safety 
has been studied in healthy human volunteers in a dose-ranging phase I-study 
(Eisenach et al. 2002). However, the present commercially available ketorolac 
or other NSAIDs should not be given intrathecally because of potentially 
neurolytic excipients (alcohol, preservatives) and potential microbiological 
impurity. 
 
2.2.8 Other targets besides COX 
 
NSAIDs may also affect other targets besides the PGHS enzyme. Interactions 
with central opioid, serotonergic and nitric oxide systems have been described 
(Björkman 1995), although they may be indirect. Different NSAIDs may also 
directly inhibit and activate transcription factors, kinases and nuclear 
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receptors. Possible targets to different NSAIDs include nuclear factor kappa B, 
activator protein-1, MAP-kinase- family, protein kinase B, heat shock protein 
and peroxisome proliferator-activated receptor γ (Kankaanranta 1995). Some 
NSAIDs may have these COX-independent functions at concentrations which 
are attained in normal clinical use in humans.  
 
 
2.3 MODE OF ANALGESIC ACTION OF PARACETAMOL 
 
Whereas there is a consensus that NSAIDs exert most of their analgesic action 
by inhibiting the COX site of the PGHS enzyme, the mechanism of 
paracetamol action is not clear. Most commonly, paracetamol is considered to 
be a centrally acting PGHS-inhibitor (Flower and Vane 1972, Greco et al. 2003, 
Ayoub et al. 2006). Paracetamol is suggested to act as a reducing cosubstrate at 
the POX site of the PGHS enzyme. At the POX site, paracetamol reduces the 
amount of Fe4+ (or OPP*+) which is needed at the COX site for the generation 
of the tyrosine-385 radical which is needed in the cyclooxygenase reaction. 
The lack of anti-inflammatory and anti-thrombotic activity is explained by the 
swamping of POX with PGG2 and by the peroxide-tone with hydroperoxide-
generating lipoxygenase enzymes (Graham and Scott 2005, Aronoff et al. 2006, 
Anderson 2008). Therefore, paracetamol is considered to have effects in the 
CNS with a strictly regulated microenvironment, but not in the periphery, in 
thrombocytes and in inflamed tissues.  
 
Additionally, paracetamol may have effects on the brain serotonergic system 
(Graham and Scott 2005, Aronoff et al. 2006, Anderson 2008); in humans, pre-
treatment with the 5-hydroxytryptamine (5-HT) antagonists tropisetron and 
granisetron seem to reduce the analgesic efficacy of paracetamol (Sandrini et 
al. 2003). Paracetamol may also affect the spinal L-arginine-nitric oxide 
system, because in animals pre-treatment with L-arginine but not with D-
arginine reverses the pain behaviour induced by intrathecal N-methyl-D-
aspartate and substance P (Björkman 1995). Paracetamol action by central 
nervous system (CNS) cannabinoid systems has also been suggested, as 
cannabinoid CB1 receptor agonist completely prevents the analgesic activity of 
paracetamol (Bertolini et al. 2006). Moreover, paracetamol seems to be partly 
metabolized to AM404, which activates vanilloid subtype 1 receptor, which is 
a ligand of cannabinoid CB1 receptor (Aronoff et al. 2006, Anderson 2008). 
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2.4 NSAIDS AND PARACETAMOL IN CLINICAL PRACTICE 
 
2.4.1 Indications for NSAIDs 
 
NSAIDs have multiple actions in the body, reducing fever, inflammation and 
pain. They have been approved for a wide variety of indications: in the 
treatment of fever, rheumatic diseases, and chronic and acute pain including 
cancer pain, dysmenorrhea, headache, dental, post-traumatic and 
postoperative pain. The widely used NSAIDs aspirin, ibuprofen and 
ketoprofen are available as OTC medications in Finland (FIMEA, NamWeb 
search). 
 
Indomethacin and ibuprofen are used in preterm infants to close the patent 
ductus arteriosus (Van Overmeire and Chemtob 2005). Aspirin is used in the 
treatment of Kawasaki disease (Baumer et al. 2006).  
 
2.4.2 Indications for paracetamol 
 
Paracetamol reduces pain and fever, but lacks anti-inflammatory action. It has 
been approved for fever reduction and for treatment of chronic and acute 
pain.  
 
2.4.3 Contraindications for and adverse effects of NSAIDs 
 
Besides having beneficial effects on pain, fever and inflammation, NSAIDs 
have some important contraindications and adverse effects. These effects are 
common to all NSAIDs, because they are mediated by PGs. The normal 
regulation of physiological functions by PGs is altered with NSAID therapy, 
because COX inhibition reduces the formation of PGs. Most children tolerate 
NSAIDs well (Lesko and Mitchell 1995), but the contraindications and adverse 
effects should be taken into account when prescribing NSAIDs to children. 
 
Constitutive COX-1 enzyme in the gastric mucosa produces PGs, which 
protect the integrity of the mucosa against gastric acid and enzymes. PGE and 
PGI increase the blood flow of mucosa, improve ulcer healing, increase the 
production of mucus and bicarbonate, and decrease the secretion of gastric 
acid. The effect of NSAIDs on gastric mucosa is also increased by ion trapping, 
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leading to intracellular accumulation of NSAIDs, which are weak acids. 
Gastric adverse effects are common in normal practice; at long-term use 
approximately 20% of patients suffer from nausea, abdominal pain, diarrhea, 
heartburn and gastrointestinal ulcers (Caruso and Bianchi Porro 1980). 
Patients at high age, with concomitant corticosteroid, selective serotonin 
reuptake inhibitor or antithrombotic medications and with previous 
gastrointestinal ulcers or with helicobacter pylori are at high risk of severe 
gastric adverse effects (Dalton et al. 2003, Hallas et al. 2006, Helin-Salmivaara 
et al. 2007). The risk of gastric adverse effects can be reduced by minimizing 
the daily dose and duration of NSAIDs therapy and by concomitant use of per 
oral PGE2, histamine-2 receptor antagonist or proton-pump inhibitor. The risk 
of gastric adverse effects is reduced by 50% when COX-2 selective NSAIDs are 
used instead of traditional agents (Hooper et al. 2004, Moore et al. 2006). 
 
In normal situations, PGs have a minor role in maintaining renal function, but 
in patients with hypovolemia, hypotension, dehydration, cardiac insufficiency 
and renal disease PGs dilate renal blood vessels and help in maintaining 
normal renal blood flow and glomerular filtration. By blocking the PG 
production and vasodilatation, NSAIDs can cause acute renal failure, which is 
usually reversible. Moreover, minor, clinically irrelevant changes in renal 
function, and sodium and water retention occur commonly with NSAID 
therapy. Long-term use of NSAIDs may also cause interstitial nephritis and 
renal papillary necrosis. These renal adverse effects occur with both COX-2-
selective and traditional NSAIDs at similar incidence (Whelton 1995, John et 
al. 2007, Lee et al. 2007). 
 
Thromboxane A (TXA) causes thrombocyte aggregation and blood vessel 
vasoconstriction in the case of bleeding and vascular injury. Since NSAIDs 
also inhibit PG production by COX-1 in thrombocytes, they increase bleeding 
time. Therefore, all NSAIDs should be used cautiously in patients with 
bleeding disorders and anticoagulant medications (Rømsing and Walther-
Larsen 1997, Cardwell et al. 2005). Moreover, COX-2 selective and traditional 
NSAIDs increase the risk of atherothrombosis, such as myocardial infarction. 
However, in patients with high risk of atherothrombosis, naproxen is assumed 
the safest NSAID (Helin-Salmivaara 2006, Kearney 2006). 
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In some asthmatics, NSAIDs cause changes in arachinoidic acid metabolism in 
the lungs. When the PG pathway is blocked by NSAIDs, AA is converted to 
cystein leukotriens, which cause bronchoconstriction and asthma attack. Some 
asthmatics (5-20%) are aspirin-intolerant, and cannot tolerate any NSAIDs 
(Lesko and Mitchell 1995, Lesko and Mitchell 1999, Lesko et al. 2002, Jenkins et 
al. 2004, Debley et al. 2005). 
 
In fetuses and newborn infants, PGs inhibit the constriction of the 
musculature in the ductus arteriosus blood vessel wall (EMEA 2005, Van 
Overmeire and Chemtob 2005). Since NSAIDs inhibit the production on PGs, 
they may cause premature closure of the ductus arteriosus. Furthermore, PGs 
play a role in uterus contractions in normal labour, so NSAIDs may cause 
protracted labour. Moreover, NSAIDs may impair fertility and affect 
organogenesis. COX-2 inhibitors may have effects on glomerulogenesis 
(Kömhoff et al. 2000). Because of these effects, NSAIDs are contraindicated in 
pregnancy during the third trimester, and use of NSAIDs is avoided in all 
stages of pregnancy. Usually NSAIDs are not used in infants under 3 months 
age, and they are contraindicated in infants with ductus arteriosus dependent 
heart disease. 
 
NSAIDs are contraindicated in severe liver insufficiency due to possible 
changes in metabolism and the risk of gastric adverse affects and bleeding 
(Davies and Anderson 1997, Kokki 2003). Moreover, the use of aspirin with 
concurrent viral infection (varicella zoster or influenza), may cause Reye 
syndrome, characterized by acute encephalopathy, hepatic steatosis and 
elevated levels of serum transaminases (Chow et al. 2003). Therefore, the use 
of aspirin is often avoided in children. 
 
Occasionally NSAIDs cause central nervous system adverse effects such as 
drowsiness, headache, dizziness, vertigo and depression (Tharumaratnam et 
al. 2000, Clunie et al. 2003). With frequent use, NSAIDs may cause medication-
overuse headache, which resolves after the withdrawal of analgesics (Diener 
and Limmroth 2004, Pakalnis et al. 2007). Skin reactions and other allergic 
reactions are rare after systemic NSAIDs, but common after topical NSAIDs 
(Lin et al. 2004). 
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2.4.4 Contraindications for and adverse effects of paracetamol 
 
Paracetamol has fewer contraindications and causes fewer adverse effects than 
NSAIDs. Because of paracetamol metabolism in the liver and liver toxicity of 
metabolites, paracetamol is contraindicated in patients with severe liver 
insufficiency. Moreover, paracetamol should be used cautiously in patients 
with any hepatic disease, severe renal insufficiency or malnutrition, and 
hypovolemia should be corrected before use (Whelton 1995). Adverse effects, 
nausea, hypotension and allergic reactions, are rare. With frequent use, 
paracetamol may cause medication-overuse headache (Diener and Limmroth 
2004, Pakalnis et al. 2007). 
 
 
2.5 NSAIDS AND PARACETAMOL IN PAEDIATRIC POSTOPERATIVE PAIN 
 
NSAIDs are widely used for postoperative pain in children older than 3 
months (Eustace and O'Hare 2007). Paracetamol is the most commonly used 
analgesic in children at all ages, including in preterm neonates (Anderson 
2004, Jacqz-Aigrain and Anderson 2006). NSAIDs and paracetamol are 
commonly combined in moderate and severe pain, because they may act 
synergistically and improve pain control (Viitanen et al. 2003, Hiller et al. 
2006, Miranda et al. 2006, Salonen et al. 2009, Merry et al. 2010). Combining 
two NSAIDs increases the incidence of adverse effects, but not the efficacy 
(Kokki 2003). 
 
In mild and moderate postoperative pain, NSAIDs and paracetamol as single 
agents or combined may perform well, with few adverse effects. In severe 
pain, NSAIDs and paracetamol are used as components of multi-modal 
analgesia, because of opioid-sparing effects and better patient satisfaction. 
Moreover, NSAIDs and paracetamol may reduce the incidence of opioid-
related adverse effects such as pruritus, sedation, respiratory depression and 
vomiting (Kokki 2003, Anderson 2004, Jacqz-Aigrain and Anderson 2006). A 
decrease in the incidence and severity of vomiting has been observed in 
patients who have undergone tonsillectomy (Cardwell et al. 2005) and 
strabismus surgery (Kokki et al. 1999). 
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2.5.1 Dosing 
 
The maturation of pharmacokinetics should be taken into account while 
prescribing NSAIDs and paracetamol to children. In newborn infants hepatic 
and renal clearance is reduced, total body water content is high, total body fat 
content is low and interindividual variation in pharmacokinetics is large, 
therefore reduced doses are needed. Most commonly hepatic clearance 
reaches adult values by the age of 6 months and renal clearance by the age of 2 
years. Sometimes children at age of 6 months to 6 years need higher body 
weight adjusted doses, because hepatic clearance is increased (Bartelink et al. 
2006, Kearns et al. 2010). However, in clinical work the dosing of most drugs, 
inclusing NSAIDs and paracetamol, is usually based on the body weight. The 
dosing of NSAIDs suggested by Kokki (2003) is presented in Table 4.  
 
Paracetamol dosing is a controversial subject. An intravenous dose of 15 
mg/kg three or four times per day and an oral dose of 15-20 mg/kg three times 
per day are commonly used (Table 5). Higher single oral doses of 40 mg/kg 
have also been studied (Anderson et al. 2001). In Finland the maximum 
recommended daily dose of paracetamol is 60 mg/kg divided in three or four 
doses over a day (FIMEA, NamWeb search).  
 
Korpela and colleagues (1999) have shown that low dose suppositories (10 - 20 
mg/kg) are ineffective in pain relief after surgery in children. In children who 
had undergone day-case surgery, ED50 was 35 mg/kg, and the use of higher 
loading dose 40 mg/kg suppositories was suggested. In further studies it was 
shown that paracetamol absorption from suppositories is slow and erratic 
(Anderson 2004), which may account for poor pain relief in some children. 
However, in Finland the maximum recommended daily dose of paracetamol 
suppositories is 60 mg/kg. Because rectal bioavailability is low (0.3-0.98) 
(Montgomery et al. 1995, Anderson 2004), it can be argued that the maximum 
recommended daily dose of suppositories should be higher. Moreover, 
previous studies suggest that long-term use at doses above 60 mg/kg may 
cause liver damage, but short-term (up to 2 days) treatment (with doses less 
than 90 mg/kg/day) is safe, although large-scale studies are required to 
confirm this (Anderson et al. 2001, Hiller et al. 2006, Kozer et al. 2006).  
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Table 4. Dosing suggestions for some NSAIDs in paediatric postoperative pain 
(age > 3 months) (Kokki 2003) 
 
 Single dose 
(mg/kg) 
Dosing interval (h) Maximum daily 
dose (mg/kg) 
Indomethacin 0.35 6-8 2 
Ibuprofen 10 6-8 40 
Ketorolac 0.3-0.5 6-8 2 
Diclofenac 1 8-12 3 
Ketoprofen 1-2 6-8 5 
 
 
 
 
Table 5. Dosing suggestions for intravenous paracetamol 
 
 
Loading dose 
Maintenanc
e dose 
Doses per 
day 
Maximum 
dose per 
day 
neonates 
28-32 weeks PCA* 
20 mg/kg 7.5 mg/kg 3  
neonates 
33–36 weeks PCA* 
20 mg/kg 7.5 mg/kg 4  
full-term neonates* 20 mg/kg 10–15 mg/kg 4  
full-term neonates, infants, 
children  
weighing <10kg ¤ 
7.5 mg/kg 7.5 mg/kg 3-4 30 mg/kg 
children  
weighing 10-33kg ¤ 
15 mg/kg 15 mg/kg 3-4 
60 mg/kg 
2 g 
children, adolescents 
weighing 33-50kg ¤ 
15 mg/kg 15 mg/kg 3-4 
60 mg/kg 
3 g 
children, adolescents, adults 
weighing >50kg ¤ 
1 g 1 g 3-4 4 g 
PCA postconceptional age 
*(Bartocci and Lundeberg 2007)  ¤(Duggan and Scott 2009, SPC Perfalgan) 
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2.5.2 Formulation 
 
In paediatric postoperative pain management, the correct formulation is 
especially important. In the immediate postoperative period, NSAIDs and 
paracetamol are best administered intravenously due to the improved dose 
accuracy (as mg/kg) and reliability, because the variability associated with 
enteral absorption is absent (Murat et al. 2005). After surgery and anaesthesia, 
in supine position, gastric emptying is delayed and vomiting is common, so 
oral formulations may have poor bioavailability or delayed absorption. 
Absorption from suppositories is sometimes variable and slow (Kokki et al. 
2003, Anderson 2004, van der Marel et al. 2004, Kyllönen et al. 2005). Because 
of the costs of intravenous paracetamol, the loading dose of paracetamol is 
sometimes given by mouth before elective surgery (Anderson et al. 2001), or at 
high dose per rectum during anaesthesia or sedation (Korpela et al. 1999). 
However, as an application for marketing authorisation of generic intravenous 
paracetamol has been submitted, the costs of intravenous paracetamol are 
expected to decrease. 
 
After recovery of gastric function, small or dispersing tablets or mixtures are 
the most preferred formulation. Intramuscular and rectal formulations are 
avoided in awake children, since children (Kokki 2003) and parents (Seth et al. 
2000) dislike them. In Finland, intravenous formulations of ketorolac, 
diclofenac, ketoprofen and paracetamol are available. Paediatric paracetamol 
formulations include oral dispersing and normal tablets, oral mixture and 
suppositories. In addition, ibuprofen oral tablets and suppositories, as well as 
ketoprofen tablets are on the market in Finland (FIMEA, NamWeb search). 
 
2.5.3 Adverse effects 
 
NSAIDs rarely cause severe adverse effects in short-term postoperative use 
(Kokki 2003, Anderson 2004, Jacqz-Aigrain and Anderson 2006). Paracetamol 
rarely causes any adverse effects in short-term use in children when 
recommended doses are not exceeded. 
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Bleeding 
 
NSAIDs may increase operative site bleeding because of effects on platelet 
aggregation. However, meta-analysis has shown that NSAIDs do not increase 
the risk of bleeding in healthy children without bleeding disorders or 
anticoagulant medications, (Rømsing and Walther-Larsen 1997, Cardwell et al. 
2005). In any case, NSAIDs are commonly administered only after the 
achievement of primary haemostasis, especially after surgery with a 
significant risk of haemorrhage. Paracetamol may have minor effects on the 
bleeding time (Niemi et al. 2000, Munsterhjelm et al. 2005), but these effects 
are considered insignificant in most cases.  
 
Asthma 
 
NSAIDs may provoke asthma attacks in sensitive asthmatics. Asthmatics with 
nasal polyps are especially prone to asthma exacerbation. However, the risk of 
an asthma attack is 0.5-5 % if the asthmatic child does not have a history of 
NSAID-provoked broncho-constriction (Lesko and Mitchell 1995, Lesko and 
Mitchell 1999, Lesko et al. 2002, Jenkins et al. 2004, Debley et al. 2005). 
Paracetamol is well tolerated in aspirin-sensitive asthmatics; only 
approximately 7% of aspirin-sensitive asthmatics react to paracetamol (Jenkins 
et al. 2004). 
 
 
2.6 DRUGS INVESTIGATED 
 
2.6.1 Indomethacin 
 
Indomethacin (Figure 2), an indole acetic acid derivative, is a traditional non-
selective COX inhibitor. It has been available in Finland in an enteral form 
since 1965 and parenteral form since 1983 (FIMEA, NamWeb search). The 
marketing authorisation of intravenous formulation was withdrawn in 
October 2007 (FIMEA, NamWeb search). Indomethacin has been shown to be 
effective and safe in postoperative pain in children at age 1-16 years 
(Maunuksela et al. 1987, Maunuksela et al. 1988), but nowadays it is not 
commonly used in paediatric postoperative pain. Intravenous indomethacin is 
sometimes used for the closure of the PDA in preterm infants, but intravenous 
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ibuprofen has recently been marketed for that purpose (SPC Pedea, Ohlsson et 
al. 2008). 
 
 
 
Figure 2. Indomethacin 
 
Pharmacokinetics 
 
Absorption of indomethacin after oral and rectal administration is complete 
and rapid, with peak plasma concentration 0.25 – 3hours (Helleberg 1981) 
(Table 6). It is highly (> 99.7%) bound to plasma proteins (Bannwarth et al. 
1990). Indomethacin is subject to extensive enterohepatic recirculation. It is 
metabolized to O-desmethyl-metabolite by CYP2C9 (Nakajima et al. 1998) and 
to N-deschlorobenzyl-metabolite. The metabolites are conjugated with 
glucuronic acid and secreted in the urine and bile (Yeh 1985). The 
pharmacokinetics of has been studied in preterm neonates (Smyth et al. 2004, 
Al Za’abi et al. 2007), infants and children (Olkkola et al. 1989). The kinetics in 
children is similar to that in adults with an elimination half-life of 6 hours 
(Olkkola et al. 1989). Lower clearance and a longer elimination half-life of 20 
hours is seen in preterm neonates, but clearance increases in the first postnatal 
six weeks and mature elimination half-life in reached (Smyth et al. 2004, Al 
Za’abi et al. 2007). 
 
Adverse effects 
 
Unique for indomethacin among NSAIDs is the high incidence of CNS 
adverse effects (AEs). Indomethacin commonly causes headache and 
dizziness, and rare cases of cognitive dysfunction, depression and psychosis 
have been reported (Tharumaratnam et al. 2000, Clunie et al. 2003). The 
mechanism by which indomethacin causes CNS AEs is unclear. Indomethacin 
has been shown to reduce cerebral blood flow in preterm infants (Mosca et al. 
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1997, Patel et al. 2000) and in healthy volunteers (Jensen et al. 1996). Either 
vasoconstriction or later observed vasodilatation in the brain may cause the 
CNS AEs. Furthermore, indomethacin and serotonin have structural 
similarities (indole-moiety). Therefore, CNS AEs may be caused by the direct 
effect of indomethacin on central neurons via the serotonin pathway, or a 
direct effect by some other mechanism, such as COX inhibition. 
 
 
Table 6. Pharmacokinetic characteristics of the investigated drugs in adults 
(Avery’s drug treatment, 1997) 
 
 Oral 
bioavailability 
(%) 
Total 
clearance 
(l/h, 70kg) 
Half-life of the 
terminal 
elimination 
phase 
(h) 
Apparent 
volume of 
distribution 
(l, 70kg) 
Indomethacin <85 6.3 6 14 
Ibuprofen <80 3.5 2.5 9.8 
Ketorolac 80 2 5.6 17.5 
Diclofenac 60 15.6 1.5 10.5 
Paracetamol 70-90 19.3 2.5 65.8 
 
 
 
2.6.2 Ibuprofen 
 
Ibuprofen (Figure 3) is a chiral phenyl propionic acid derivative, a “profen”, 
structurally similar to naproxen and ketoprofen, and non-selective COX 
inhibitor. It was launched in Finland in 1974 (FIMEA, NamWeb search), and 
since 1994 it has been the most commonly used analgesic in Finland (NAM, 
Finnish Statistics on Medicines 1990-2007). Ibuprofen is commonly used in 
postoperative pain management in children (Eustace and O'Hare 2007). It has 
been shown to be efficient after various operations, including tonsillectomy 
(Maunuksela et al. 1992b, Kokki et al. 1994, Pickering et al. 2002, Kokki 2003, 
Viitanen et al. 2003), in pain due to acute otitis media (Spiro et al. 2006), 
traumas (Clark et al. 2007), and in fever reduction (Lesko and Mitchell 1995, 
Goldman et al. 2004). Intravenous ibuprofen is used for the closure of the PDA 
(EMEA 2005, Ohlsson et al. 2008). 
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Figure 3. Ibuprofen 
 
The stereoisomers of ibuprofen may have different actions (Evans 1996). It 
seems that S-ibuprofen but not R-ibuprofen elicits analgesic actions in the 
CNS, as demonstrated after intrathecal administration in rat formalin test and 
substance P-induced hyperalgesia (Malmberg and Yaksh 1992, Yaksh et al. 
2001). Moreover, systemically given S-ibuprofen (dexibuprofen) has analgesic, 
antipyretic and anti-inflammatory actions. The actions of systemic R-
ibuprofen are difficult to estimate, because unidirectional bioconversion of 
approximately 60% of the R to S isomer occurs (Kelley et al. 1992, Kyllönen et 
al. 2005).  
 
Pharmacokinetics 
 
Ibuprofen is completely and rapidly absorbed from different oral 
formulations, with peak plasma concentrations 0.25 – 3 h after administration. 
It is highly, > 99% bound to plasma proteins, mainly albumin. Ibuprofen is 
metabolised to inactive hydroxy and carboxy metabolites by CYP2C9 and 
CYP2C8, and partly conjugated with glucuronic acid. The metabolites are 
excreted mainly in the urine (Davies 1998). The elimination half-life of 
ibuprofen is 2 hours in children and adults (Davies 1998), but markedly 
prolonged elimination (30 hours) and decreased protein binding occurs in 
preterm and term neonates (Aranda et al. 1997, EMEA 2005, Hirt et al. 2008). 
 
Adverse effects 
 
Ibuprofen is considered to be one of the safest NSAIDs. Epidemiological 
studies have shown that short-term low-dose ibuprofen causes less gastro-
intestinal complications than other NSAIDs (Henry et al. 1996, Hernandez-
Diaz and Rodriguez 2000, Lewis et al. 2002). Moreover, large-scale studies 
show ibuprofen to be safe also in children and toddlers (Lesko and Mitchell 
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1995, Lesko and Mitchell 1999). However, the safety is dose-dependent and 
the incidence of adverse effects increases with increasing dose. 
 
2.6.3 Ketorolac 
 
Ketorolac (Ketorolac Tromethamine) (Figure 4) is a chiral pyrrole acetic acid 
derivative and a non-selective COX inhibitor. It has been marketed in Finland 
since 1991 (FIMEA, NamWeb search), and is indicated for the treatment of 
moderate and severe postoperative pain, for a maximum of two days (SPC 
Toradol). Ketorolac has been proved efficient in pain relief in children after 
various operations, including herniotomy and tonsillectomy (Forrest et al. 
1997). The onset of analgesic action is slower, but is sustained longer than with 
morphine (Rice et al. 1991, Maunuksela et al. 1992a, Rice et al. 1995). 
 
 
 
Figure 4. Ketorolac 
 
Two stereoisomers of ketorolac seem to have different actions. S-ketorolac 
accounts for the analgesic and anti-inflammatory actions, while R-ketorolac is 
ineffective as an analgesic and anti-inflammatory agent and has no effect on 
COX (Mroszczak et al. 1996). Bioinversion R→S does not occur in humans, 
whereas inversion S→R does to some extent (6.5 %) (Mroszczak et al. 1996). 
However, there are major differences in inversion rates between different 
animal species, and inversion in the CNS has not been studied in humans or 
animals. 
 
Pharmacokinetics 
 
Ketorolac is completely and rapidly absorbed from intravenous, 
intramuscular and oral formulations. It is extensively (>99 %) bound to plasma 
proteins (Gillis and Brogden 1997). Ketorolac is metabolised by 
glucoronidation and para-hydroxylation. The metabolites (40%) and ketorolac 
(60%) are mainly excreted in the urine. Some age-related differences in 
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pharmacokinetics may occur, but the elimination half-life is similar (Olkkola 
and Maunuksela 1991, Forrest et al. 1997, Hamunen et al. 1999, Zuppa et al. 
2009). The elimination half life is 5 hours in children and adults, but longer in 
the elderly and in patients with renal impairment (Gillis and Brogden 1997).  
 
Adverse effects 
 
The adverse effects associated with ketorolac are similar to those of other 
NSAIDs. Ketorolac is most extensively used in postoperative pain 
management, for short-term, in-hospital patients. The major concerns are 
operative site bleeding, renal adverse effects, upper gastrointestinal 
lesions/bleeding and allergic reactions. However, when patients with NSAID-
related risk factors and adverse effects are excluded, the incidence of severe 
adverse effects is low, similar to other NSAIDs (Maunuksela et al. 1992a, 
DeAndrade et al. 1994, Forrest et al. 1997). 
 
Intrathecal administration 
 
Intrathecal administration of ketorolac has been studied in animals (Yaksh et 
al. 2004) and healthy volunteers (Eisenach et al. 2002). The study in rats and 
dogs confirmed the long term (1 month) safety of lumbar intrathecal ketorolac 
infusion (Yaksh et al. 2004). In a phase I dose-ranging human study, no 
adverse effects were noted (Eisenach et al. 2002). However, special 
preparations of ketorolac are required for intrathecal administration, because 
intravenously intended formulations may contain ethanol, preservatives and 
traces of bacteria and bacterial products. 
 
2.6.4 Diclofenac 
 
Diclofenac (Figure 5), a phenylacetic acid derivative, is a non-selective COX 
inhibitor. It has been available in Finland in enteral form since 1977 and 
parenteral form since 1984 (FIMEA, NamWeb search). In clinical use, 
intravenous diclofenac is added to buffered solutions, because there is a risk of 
supersaturation and crystal formation (SPC Voltaren). Diclofenac has been 
shown to be effective in postoperative pain. It reduces the need for morphine 
in children after appendicectomy (Morton and O'Brien 1999), strabismus 
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surgery (Wennström and Reinsfelt 2002), adenoidectomy (Baer et al. 1992) 
herniotomy and orchidopexy (Ryhänen et al. 1994).  
 
 
 
Figure 5. Diclofenac 
 
Pharmacokinetics 
 
Diclofenac is rapidly and completely absorbed from oral formulations (0.25 – 3 
h and 90%), and from suppositories in adults and children (Davies and 
Anderson 1997, van der Marel et al. 2004). After oral absorption it undergoes 
first pass metabolism, with 60% of the drug reaching systemic circulation. 
Diclofenac is extensively (>99.7%) bound to plasma proteins, mainly albumin. 
Diclofenac is metabolized by CYP2C9 to hydroxyl metabolites and partly 
further conjugated to glucuronide and sulphate metabolites. The metabolites 
are excreted mainly in the urine (Davies and Anderson 1997). In adults and 
children the elimination half-life is 1 - 2 h (Korpela and Olkkola 1990, Davies 
and Anderson 1997).  
 
Adverse effects 
 
Diclofenac may cause adverse effects that are typical of all NSAIDs. However, 
adverse effects are rare in children in short-term use (Standing et al. 2009). 
Additionally, intramuscular injection of diclofenac rarely causes Nicholau 
syndrome, which is characterised by cutaneous and muscular necrosis at the 
site of injection. The aetiology of Nicholau syndrome has been suggested to 
involve intra- or peri-arterial drug injection, leading to ischemia of the skin 
and the muscle (Stricker and van Kasteren 1992, Ezzedine et al. 2004, Luton et 
al. 2006). 
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2.6.5 Paracetamol 
 
Paracetamol (acetaminophen, Figure 6) belongs to the group of anilides. The 
oral formulation of paracetamol has been marketed in Finland since the 1960s 
(FIMEA, NamWeb search). Paracetamol is the most commonly used analgesic 
in many countries. In Finland, the use of paracetamol is rising (NAM, Finnish 
Statistics on Medicines 01/2009-06/2009 and 1990-2007). There are two 
intravenous paracetamol formulations available. Intravenous prodrug 
formulation (Pro-Dafalgan) contains propacetamol (2g), which is hydrolyzed 
rapidly to paracetamol (1g) by the plasma esterase. Another intravenous 
formulation (Perfalgan) containing paracetamol has been shown to be as 
effective as the prodrug formulation, but with less injection site pain (Murat et 
al. 2005). It has been marketed in Finland since 2002.  
 
 
 
Figure 6. Paracetamol 
 
Paracetamol has been shown to reduce the need for opioids and provide better 
pain management in children after various operations, including 
tonsillectomy (Anderson et al. 2001), herniotomy (Korpela et al. 1999, Murat et 
al. 2005) and orthopaedic operations (Granry et al. 1997). Some studies on 
postoperative pain relief have found non-superiority to placebo. The lack of 
pain relief in some studies is probably due to study design, such as opioid use 
and too low paracetamol doses (Hamunen and Kalso 2005, Korpela et al. 
2007). 
 
Pharmacokinetics 
 
Paracetamol is rapidly and completely absorbed from oral formulations, 
whereas absorption from suppositories is erratic and slow (Montgomery et al. 
1995, Anderson 2004). Degree of binding in blood is low (< 20%) (Milligan et 
al. 1994). Paracetamol is metabolized in the liver to glucuronide and sulphate 
conjugates, which are secreted in the urine. In adults, 60-80% and 20-30% of 
paracetamol is metabolized to glucuronide and sulphate conjugates, 
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respectively. In children, sulphate conjugation is more important and 
glucoronidation reaches adult levels only after birth (van der Marel et al. 
2003b). A small part of paracetamol is metabolized through oxidation to 
hepatotoxic N-acetyl-p-benzoquinoneimine, which is conjugated with 
glutathione and further excreted in the urine as cysteine and mercapturic acid 
conjugates (Forrest et al. 1982). Additionally, minimal amounts of paracetamol 
are excreted in the urine unchanged. The elimination half-life is 3.5 hours in 
neonates, 1.5 – 2 hours in children (Anderson et al. 2005) and 2.5 hours in 
adults (Forrest et al. 1982, Duggan and Scott 2009). Clearance is reduced in 
preterm neonates when compared with term neonates (Table 5) (Allegaert et 
al. 2004a). 
 
Adverse effects 
 
The safety of paracetamol has been proved in large-scale studies, including in 
children (Lesko and Mitchell 1995 and 1999). The adverse effects (hypotension, 
nausea and elevated liver enzymes) are rare. Allergic reactions are very rare, 
and cases of blood count changes have been reported (SPC Perfalgan). 
Paracetamol may also cause kidney failure, especially in dehydrated patients 
(Whelton 1995). 
 
Paracetamol may cause liver damage at overdoses (above 7.5 g in adults, and 
above 140 mg kg-1 in children), because glutathione is depleted and toxic 
metabolite N-acetyl-p-benzoquinoneimine is bound to liver cells (Kozer et al. 
2006). Treatment of overdose may include N-acetyl cysteine and liver 
transplantation (Hoppu 2002, Koivusalo et al. 2002, Kozer et al. 2006). Liver 
damage has been claimed to occur more common in alcoholics and 
malnourished patients (Prescott 2000). Overdoses may also cause 
nephrotoxicity, which is suggested to occur because of glutathione depletion 
in the kidneys (Boutis and Shannon 2001). Since paracetamol is available over-
the-counter, poisoning is common in some countries. It is involved in 
approximately 50% of self poisonings in the UK (Camidge et al. 2003), and the 
annual incidence of paracetamol overdose requiring emergency department 
visit is 46 per 100 000 population in Canada (Myers et al. 2007). In Finland, 
serious paracetamol toxicity is rare (Isoniemi 2003). 
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2.7 BARRIERS BETWEEN BLOOD AND THE CENTRAL NERVOUS SYSTEM 
 
The microenvironment of the CNS neurons is strictly regulated. Neurons are 
bathed in the interstitial fluid, which is separated from the cerebrospinal fluid 
by the ependyma. CNS fluid compartments are insulated from arterial blood 
by the BBB, the choroid plexus and the blood-spinal barrier. 
Circumventricular organs, regulating physiological functions such as the fluid 
balance, the circadian rhythm and vomiting, lack the BBB (Edwards 2001, 
Abbott 2004). The interfaces between fluid compartments in the CNS are 
shown in Figure 7. 
 
2.7.1 History 
 
Ehrlich and Goldmann were the first to recognize a barrier between blood and 
the central nervous system. Ehrlich (1885) noticed that intravenous blue dye 
stained the whole body except for the brain. Goldmann (1909) observed that 
intravenous trypan blue stained the meninges and the choroid plexus, but not 
the brain and the CSF. Moreover, Goldmann (1913) discovered that after 
intraventricular trypan blue injection, the whole brain was stained. 
 
2.7.2 Definitions of the BBB and the BCSFB 
 
The blood-brain barrier is defined as the site of exchange between blood, in 
the CNS capillaries, and the CNS extracellular fluid. The blood-cerebrospinal 
fluid-barrier (BCSFB) is defined as the site of exchange between blood in the 
capillaries and the CSF. One part of the BCSFB is the choroid plexus (CP). 
 
2.7.3 Cerebrospinal fluid 
 
Cerebrospinal fluid is a clear, colourless fluid contained within the ventricles 
and the subarachnoidal spaces around the CNS. CSF is formed by the CP, a 
leaf-like, highly vascular structure situated in the walls of the lateral ventricles 
and the roofs of the third and fourth ventricles. A smaller part of the CSF may 
be drained from the brain interstitial fluid after ependyma filtration. The rate 
of CSF formation in adults is approximately 500 ml per day (Davson and Segal 
1996). The total intracranial volume of the CSF is 165 ml (range 62 - 267 ml) in 
young adults (Tanna et al. 1991). The volume of lumbosacral CSF is 36 ml 
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(range 11 – 61 ml) (Sullivan et al. 2006). When adjusted to body weight, the 
volume of intracranial CSF is constant in children older than 3 months 
(Pfefferbaum et al. 1994) and the rate of formation is similar to that in adults 
(Blomquist et al. 1986, Johnston and Teo 2000). 
 
From the paired lateral ventricles, CSF flows via the foramina of Monro into 
the third ventricle. The third ventricle is connected via the aqueduct of Sylvius 
to the fourth ventricle, which opens via the foramen of Magendie and the 
foramina of Luschka to the subarachnoidal space. CSF in the subarachnoidal 
space surrounds the spinal cord inside the spinal canal, and caudally 
continues until the sacrum. CSF is drained mainly to the dural venous blood 
stream via valvular arachnoid granulations (Davson and Segal 1996), although 
a part may be drained to the lymphatic system (Koh et al. 2005). 
 
2.7.4 Structure of the BBB  
 
The BBB (Figure 8) consists of brain capillary endothelial cells, basement 
membrane, pericytes and astrocyte foot processes. Brain capillary endothelial 
cells are polarized, non-fenestrated endothelial cells, which are interconnected 
by tight junctions. Pericytes cover 20 – 30 % of the capillary surface and have a 
continuous basement membrane with brain capillary endothelial cells. 
Astrocytic endfeet project near the capillary (Davson and Segal 1996, Graff 
and Pollack 2004, de Boer and Gaillard 2007). 
 
2.7.5 Structure of the CP 
 
The choroid plexus (Figure 9) consists of capillary endothelial cells, stroma, 
basement membrane and choroid epithelium (ependyma). Each CP villus 
contains centrally packed blood vessels surrounded by stroma with pial cells 
and collagen fibrils. The capillary endothelial cells are polarized and 
fenestrated. Each villus is surrounded by choroid epithelium, which lays over 
a basement membrane. Choroid epithelium is a layer of tightly packed 
cuboidal epithelial cells, which are connected by tight junctions. Choroid 
epithelial cells contain cilias at the apical side, facing the CSF. The choroid 
epithelial cell layer is continuous with the ependyma, which lines the 
ventricles and separates the CSF from the brain (Davson and Segal 1996, Graff 
and Pollack 2004, de Boer and Gaillard 2007). 
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Figure 7. Diagram showing the interfaces between different fluid 
compartments in the central nervous system (CNS). Broken lines represent the 
barriers: the blood-brain barrier (BBB), the ependyma and the blood-
cerebrospinal fluid-barrier (BCSFB), including the choroid plexus (CP). Th 
paths of fluid movement are marked with arrows. Circumventricular organs 
(CVO) are not separated from blood by barriers. Redrawn and modified from 
de Boer and Gaillard (2007). 
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Figure 8. Schematic cross-section of the blood-brain barrier (BBB). Brain 
capillary lumen is surrounded by the brain capillary endothelial cells (BCEC) 
with tight junctions (TJ), pericytes (P), basement membrane (BM), astrocytic 
endfeet (A). Redrawn and modified from de Boer and Gaillard (2007). 
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Figure 9. Schematic cross-section of the choroid plexus. Two choroid plexus 
villi contain a fenestrated capillary. The capillary (Cap) is surrounded by 
stromal connective tissue (Str), composed of collagen fibres, fibroblasts, 
dendritic cells and macrophages. The outer simple cuboidal epithelial cells 
(Cub) lie on a basement membrane. The cuboidal cells are connected by tight 
junctions and bear microvilli and cilia at their apical side. Kolmer cells 
(epiplexus cells) lie on the ventricular surface of the cuboidal cells. Redrawn 
and modified from Strazielle and Ghersi-Egea (2000). 
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2.7.6 Functions of the barriers 
 
The name ‘barrier’ originates from the earliest experiments (Ehrlich 1885, 
Goldmann 1909), where dyes failed to pass from blood to the CNS. In further 
studies, the BBB and BCSFB have been shown to have more intricate 
regulatory actions, by which the CNS homeostasis is maintained. The barriers 
i) regulate ionic homeostasis, ii) restrict small hydrophilic molecule 
permeation, iii) facilitate influx and efflux transport by specific carriers, iv) 
restrict and regulate endocytotic permeation of large molecules, v) separate 
peripheral and central neurotransmitter pools and vi) provide immune 
privilege to the CNS (Davson and Segal 1996, Abbott 2004).  
 
2.7.7 Immature barriers 
 
It is widely believed that the BBB and CP are immature in neonates (Saunders 
et al. 1999). The schedule for the development of the barrier structure and 
function in humans has not been established (Saunders et al. 2000, 
Dziegielewska et al. 2001). It has been hypothesized that small lipophilic 
molecules may diffuse through the barriers more readily in the fetal brain than 
in the adult brain. It has also been suggested that the “sink action” increases 
with age and therefore brain bioavailability decreases with age. 
 
Also other considerable central nervous system maturation occurs during the 
postnatal period, and physiological processes undergo maturation. The 
cerebral (cortical) metabolic rate increases postnatally until the age of 3-4 years 
when it reaches levels twice those observed in adults (Albert et al. 1999). 
Moreover, the cerebral blood flow is reduced in the first 6 months of life, then 
increases to peaks at age 3 to 4 years, and thereafter decreases to adult levels 
at the age of 9 years (Zwienenberg and Muizelaar, 1999). Additionally, the 
relative size and weight of brains is larger in younger and smaller children 
than bigger and older children and adults (Albert et al. 1999). These factors 
may have an effect on the central nervous system permeation of compounds, 
and therefore small children may have higher CNS bioavailability of some 
drugs than adults. However, knowledge on maturation of CNS 
pharmacokinetics in children is sparse. 
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2.7.8 Mechanisms of barrier permeation 
 
Components may cross the BBB and the BCSFB by many mechanisms (Figure 
10). Physicochemical properties and the pharmacokinetics of the drug 
determine whether the drug reaches the site of the BBB and the BCSFB. 
Therefore, absorption, distribution, metabolism and elimination have major 
impacts on barrier permeation. Furthermore, cerebral blood flow also has 
effects on BBB and BCSFB permeation (de Lange and Danhof 2002, de Boer et 
al. 2003). 
 
Transcellular diffusion 
 
Small non-charged lipophilic molecules may cross the barriers by passive 
transcellular diffusion (Davson and Segal 1996). Passive diffusion can be 
predicted by Abraham’s method with 19 descriptors (Zhao et al. 2007) and by 
Lipinski’s rule of five (Lipinski et al. 2001). Lipinski’s rule (Lipinski et al. 2001) 
predicts poor permeation when there are more than 5 H-bond donors and 
more than 10 H-bond acceptors, when the molecular weight is more than 500 
g mol-1 and when the calculated LogP is greater than 5. The rule excludes 
compound classes that are substrates for biological transporters. In general, 
passive diffusion leads to equilibrium with drug in plasma and in the brain or 
the CSF. However, only the free concentration of a drug is available for 
diffusion so protein binding affects the amount of unbound drug available for 
diffusion.  
 
Paracellular diffusion 
 
Paracellular diffusion does not occur at the BBB or the BCSFB (Davson and 
Segal 1996). At the BBB, it is restricted by the tight junctions between brain 
capillary endothelial cells. At the CP, the fenestrated capillary endothelial cells 
permit it, but choroid epithelial cells restrict it by the tight junctions.  
 
Carrier-mediated transport 
 
Compounds may cross the BBB and BCSFB by carrier-mediated transport 
(Davson and Segal 1996, de Boer et al. 2003, Graff and Pollack 2004), which 
requires energy (Adenosine Triphosphate (ATP) -dependent) or transport of 
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another compound (symport or antiport). Influx transport systems facilitate 
the transport of many essential compounds in to the brain. There are specific 
transporters for glucose, ions and different types of amino acids. Efflux-
transport mechanisms facilitate the elimination of metabolites and other 
components from the brain. Efflux transporters include P-glycoprotein (P-gp), 
multidrug resistance-associated protein (MRP), organic cation transporters 
(OCT) and organic anion transporters (OAT). 
 
Metabolic activity 
 
Cells at the BBB and the BCSFB express many metabolic enzymes, which act 
as a functional barrier (de Lange and Danhof 2002, Graff and Pollack 2004). 
Enzymes catalyzing phase I (cytochrome P450 (CYP), monoamine oxidase 
MAO, alcohol dehydrogenase family) and phase II reactions (UDP-
glucuronosyltransferases UGTs, sulfotransferases STs, glutathione-S-
transferases, GSTs) have been found in the brain capillary endothelial cells 
and at the CP (Ghersi-Egea and Strazielle 2001, Strazielle et al. 2004, Ghersi-
Egea et al. 2006, Gradinaru et al. 2009). 
 
Endocytotic transport 
 
Endocytotic transport includes fluid-phase, adsorptive and receptor-mediated 
endocytosis (Davson and Segal 1996). In general, vesicular activity is down 
regulated at the BBB and BCSFB. However, transferrin, insulin, low-density 
lipoproteins and certain proteins cross the barriers by endocytosis.  
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Figure 10. Diagram showing transport mechanisms across the barriers. A: 
transcellular diffusion. B: paracellular diffusion. C: carrier-mediated transport: 
C1: influx, C2: efflux. D: metabolism. E: endocytosis: E1: fluid-phase 
endocytosis, E2: adsorptive endocytosis, E3: receptor-mediated endocytosis. 
Redrawn and modified from Wolka et al. (2003).  
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2.8 PENETRATION OF NSAIDS AND PARACETAMOL INTO THE CNS 
 
There are some human studies on NSAID and paracetamol penetration into 
the CSF. The results are summarized in this section.  
 
2.8.1 Transcellular diffusion of NSAIDs 
 
Some physico-chemical characteristics of the study drugs are presented in 
Tables 7-8. NSAIDs are small molecules with a molecular weight of 200 – 360 
g/mol. The logP for NSAIDs is 2.7-4.4, and they have fewer than 5 H-bond 
donors and 10 H-bond acceptors. Therefore, Lipinski’s rule of five (Lipinski et 
al. 2001) does not predict poor permeation.  
 
NSAIDs are lipophilic molecules; their N-Octanol – water partition coefficient 
in pH 7.4 (logD7.4) is 0.4 – 1.2. This would predict good permeation by 
diffusion. The relationship between drug lipophilicity and CSF diffusion was 
evaluated by Péhourcq and coworkers (2004). The discovered relationship was 
parabolic: at lipophilicity index log kIAM between 1.1 and 1.7, the drug entered 
the CSF easily; the CSF/plasma (AUC) ratio was above 1. With log kIAM less 
than 1.1 or above 1.7, the CSF/plasma ratio was below 1. The values log kIAM 
1.1 and 1.7 represent logP values of approximately 2.64 and 4.25 (Péhourcq et 
al. 2003). 
 
NSAIDs are weak acids and their pKa dissociation constants range from 3.5 to 
4.9. Calculated with the Henderson-Hasselbalch equation, only 0.01 – 0.3 % of 
NSAIDs in plasma is in unionized form. This limits NSAID permeation, since 
only the unionized, non-charged fraction may diffuse through the barriers.  
 
NSAIDs are extensively, more than 99%, bound to plasma albumin. Protein 
binding has a major effect on NSAIDs penetration in the CSF (Parepally 2005). 
Parepally studied brain concentrations in rats after in situ perfusion, at 
albumin levels matching 0, 1%, 10% and 100% of normal. He discovered that 
ibuprofen, indomethacin and flurbiprofen concentrations in the rat brain 
correlated well with free drug concentration in the plasma. Furthermore, 
young children (under 2 years old) have lower plasma albumin concentrations 
(Gomez et al. 1984), and therefore unbound NSAID concentrations in plasma 
may be higher and also result in higher CSF concentrations.  
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NSAIDs may bind to proteins, mainly to albumin, also in the CSF. The 
albumin concentration in the CSF is low, approximately 0.5% that of plasma 
(ISLAB, 2009). Protein binding in the CSF results in higher concentration 
levels, since the unbound plasma drug reaches equilibrium with the unbound 
CSF concentration. There is one previous study on indomethacin binding to 
proteins in the CSF (Müller et al. 1991). Müller and colleagues studied the 
binding of indomethacin to CSF proteins by equilibrium dialysis, after adding 
indomethacin to pooled CSF samples from ten patients. They found that 
indomethacin is 40% bound to albumin in the CSF. Furthermore, the protein 
binding of NSAIDs in the CSF can be extrapolated from the plasma data by 
using binding equations. Additionally, young children (under the age of 4-6 
months) have higher CSF protein concentrations, and therefore may have 
higher total concentrations of NSAIDs in the CSF (Biou et al. 2000, Wong et al. 
2000). 
 
2.8.2 Transcellular diffusion of paracetamol 
 
Paracetamol is a small molecule. The molecular weight, 150 g/mol, is half that 
of NSAIDs. The logP for paracetamol is 0.5, and it has less than 5 H-bond 
donors, and 10 H-bond acceptors. Therefore, Lipinski’s rule of five (Lipinski et 
al. 2001) does not predict poor permeation. 
 
Paracetamol is lipophilic and it has a logD7.4 of 0.4. It is a weak acid, which is 
99 % unionized in plasma, making it capable of diffusing the barriers. 
Paracetamol is has a low degree of binding to erythrocytes and plasma 
proteins at therapeutic concentrations (<20%) (Milligan et al. 1994), which also 
suggests good availability for permeation to the CNS. 
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Table 7. Physicochemical characteristics of some NSAIDs and paracetamol 
(NLM ChemIDplus) 
 
 molecular weight 
(g/mol) 
Number of H-bond 
donors 
Number of H-bond 
acceptors 
Indomethacin 358 1 4 
Ibuprofen 206 1 2 
Ketorolac 255 1 4 
Diclofenac 296 2 3 
Ketoprofen 254 1 3 
Paracetamol 151 2 2 
 
 
 
 
Table 8. Physicochemical characteristics of some NSAIDs and paracetamol: 
pKa dissociation constant, unionized drug percent in plasma pH 7.4, logP 
(intrinsic partition coefficient determined at pH 2.0) and logD7.4 (apparent 
partition coefficient determined at pH 7.4) 
 
 pKa 
Dissociation 
Constant * 
Unionized 
drug in 
pH=7.4 (%) 
logP logD7.4 
Indomethacin 4.5 0.13 4.27¤ 0.91 ¤ 
Ibuprofen 4.91 0.32 3.50¤ 1.07 ¤ 
Ketorolac 3.49 0.012 2.74 + 0.40 + 
Diclofenac 4.15 0.056 4.40¤ 1.22 ¤ 
Ketoprofen 4.45 0.11 3.12¤ -0.25¤ 
Paracetamol 9.38 98.95 0.4 * 0.4 a 
a. because paracetamol is 98.95% unionized in plasma pH=7.4, logD7.4 ≈ logP 
*(NLM PubChem), ¤(Barbato et al. 1997)), +(Jett et al. 1999). 
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2.8.3 Interaction with transport systems 
 
There are few studies on NSAID and paracetamol interactions with 
transporter systems. There is evidence of ibuprofen, indomethacin and 
ketoprofen transport by organic anion transporters (OAT1 and OAT3) in cell 
cultures (Khamdang et al. 2002). Diclofenac but not paracetamol BBB 
permeation in rats has been suggested to involve a transporter such as OAT3 
(Fukuda et al. 2005). Both OAT1 and OAT3 are present at the BBB and the 
BCSFB as apical efflux proteins (de Boer et al. 2003, Graff and Pollack 2004). 
The BBB ibuprofen transport has been shown to be in part self-saturable, and 
inhibited by indomethacin in rats (Parepally et al. 2006). Parepally et al. 
suggest that ibuprofen transport in the brain involves many transporters or an 
as yet unidentified transporter. They found no evidence of a saturable 
component for either indomethacin or flurbiprofen BBB transport. NSAIDs 
may also interact with multidrug resistance associated protein (MRP) and 
organic cation transport protein (OCT) action (Khamdang et al. 2002, Reid et 
al. 2003), which have been found at the BBB and the BCSFB facilitating efflux 
(MRP and OCT) and uptake (OCT) actions (de Boer et al. 2003, Graff and 
Pollack 2004).  
 
2.8.4 Indomethacin 
 
Indomethacin concentrations in the CSF have been evaluated by Dittrich et al. 
(1984) and Bannwarth et al. (1990). Dittrich and coworkers (1984) detected no 
indomethacin in the CSF, probably because their assay had a high lower limit 
of quantification (50 µg/l). Bannwarth and coworkers (1990) administered an 
intramuscular injection of 50 mg indomethacin (0.72 mg/kg) to 52 adult 
patients who underwent lumbar puncture for myelography. Indomethacin 
concentrations in the CSF ranged between 1.0 and 11.9 µg/l at 30 minutes to 12 
hours. Two high observations of indomethacin concentrations in the CSF at 2 
and 4 hours have a major effect on the means of the concentrations (Figure 11). 
Therefore, it seems that the peak values (5 µg/l) occurred at 1 to 4 hours after 
administration. The median of ratio CSF to total plasma was 0.0048 and the 
median of the ratio CSF to free plasma was 1.68. The ratio CSF to free plasma 
was above 1 in all samples at 3 to 12 hours after administration.  
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Figure 11. Indomethacin concentrations in the CSF in 52 adults after 
intramuscular indomethacin 50 mg (0.72 mg/kg) (Bannwarth et al. 1990). 
There are two high concentrations at 2 and 4 hours, which skew the mean 
observations at those times. 
 
 
 
 
2.8.5 Ibuprofen 
 
Penetration of ibuprofen enantiomers in the CSF has been studied by 
Bannwarth and coworkers (1995). They administered an oral dose of 800 mg 
racemic ibuprofen (corresponding to 11.4 mg/kg) to 46 adult patients who 
were suffering from nerve-root compression pain and were undergoing 
myelography. Ibuprofen was undetectable in samples at 30 minutes, but 
peaked at 3 hours at mean concentrations of 168 and 315 µg/l for R(-) and S(+) 
ibuprofen, respectively. The CSF concentrations exceeded unbound plasma 
concentrations at 1.5 to 8 hours. The AUC CSF to total plasma ratio was 0.009 
and 0.15 for the R(-) and S(+) ibuprofen, respectively. 
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2.8.6 Ketorolac 
 
Ketorolac concentrations in the CSF have been studied by Rice and coworkers 
(1993). Altogether 29 adult patients undergoing spinal anaesthesia received 
intramuscular ketorolac 90 mg (corresponding to 1.2 mg/kg). Ketorolac 
concentrations in the CSF ranged between 0.4 and 5.7 µg/l (median 2.1 µg/l) at 
1 to 4.5 hours. The ratio of CSF to total plasma was 0.00007 – 0.00182 (0.00034). 
 
2.8.7 Diclofenac 
 
Diclofenac concentrations in the CSF have been measured in two adult 
patients after intramuscular injection of diclofenac 75 mg (Zecca et al. 1991). 
The CSF concentrations were 3.54 and 8.50 µg/l, at 2 and 12 hours, 
respectively. The concentration ratios of CSF to total plasma were 0.003 and 
0.08. 
 
2.8.8 Other NSAIDs 
 
The penetration of ketoprofen in the CSF has been studied in children 
(Mannila et al. 2006, Kokki et al. 2002) and adults (Netter et al. 1985). Netter 
and coworkers (1985) administered intramuscular ketoprofen 100 mg to 36 
adults suffering from sciatica. They detected ketoprofen in the CSF at 15 
minutes to 13 hours after drug administration, with a peak at 3-5 hours. From 
the 2nd to the 13th hour the CSF concentrations were in equilibrium with the 
free plasma levels.  
 
Kokki and coworkers (2002) sampled the CSF 30 minutes after oral ketoprofen 
1 mg/kg from ten children (age 9 months – 7 years) undergoing spinal 
anaesthesia. They detected ketoprofen in only one CSF sample, because of the 
insensitive analytical method that had a lower limit of quantification of 20 
ηg/ml (Hannu Kokki, personal communication). Mannila et al. (2006) 
measured ketoprofen concentrations in the CSF after intravenous ketoprofen 1 
mg/kg in twenty-one children undergoing spinal anaesthesia. Ketoprofen 
concentrations were 1.4 -24 ηg/ml, with a rising trend during 7-67 minutes. 
Ketoprofen concentrations in the CSF and protein-free plasma reached 
equilibrium at one hour.  
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CSF concentrations of oxyphenbutazone, pirprofen, diflunisal, rofecoxib, 
celecoxib, valdecoxib and parecoxib have also been evaluated (Gaucher et al. 
1983, Zecca et al. 1988, Nuernberg et al. 1991, Cohen et al. 1998, Buvanendran 
et al. 2005, Dembo et al. 2005, Mehta et al. 2008). Lipinski’s rule of five 
(Lipinski et al. 2001) suggests that coxib barrier permeation is not poor 
(molecular weights 314-381 g mol-1, logP 3.2-3.9, and up to 1 H-bond donors, 
and up to 8 H-bond acceptors). For coxibs, plasma protein binding is the major 
determinant of CNS penetration; celecoxib, rofecoxib and valdecoxib reach 2-3 
times higher CSF concentrations than unbound plasma concentrations 
(Dembo et al. 2005).  
 
2.8.9 Paracetamol 
 
The penetration of paracetamol in the CSF has been studied in children, adults 
and the elderly. Bannwarth and coworkers (1992) administered intravenous 
propacetamol 2g, corresponding to paracetamol 1g and 14 mg/kg, to 43 adult 
patients who underwent myelography. Paracetamol concentrations in the CSF 
ranged between 0.78 and 9.04 mg/l at 20 minutes to 12 hours. The highest 
concentrations were measured between 45 min and 5 hours. The CSF 
concentrations exceeded plasma concentrations at 3 hours and later.  
 
Moreau and coworkers (1993) investigated the CSF concentrations of 
paracetamol in elderly patients with continuous spinal anaesthesia. They 
detected CSF concentrations ranging between 1.32 and 8.16 mg/l at 15 minutes 
to 6 hours. The peak occurred at 3 hours after intravenous propacetamol 2g, 
corresponding to paracetamol 1g. 
 
Anderson et al. (1998) studied the CSF concentrations of oral paracetamol 
elixir 40 mg/kg in nine ventilator-dependent children aged 5 months – 12 
years with external ventricular drains. The typical peak CSF concentration was 
20 mg/l at 2.5 hours. Anderson and coworkers estimated a plasma to CSF 
standardized (to 70 kg) equilibration half-time of 0.72 h (CV 117%) 
(NONMEM), which is less than that estimated for an effect compartment 
explaining antipyresis (0.99 h). They suggest that this may indicate that 
paracetamol requires more time to act on receptors in the CNS. Anderson et 
al. (1998) compared pharmacokinetic data from children and adults 
(Bannwarth et al. 1992) and found a longer teq of 2.1 h in adults. However, 
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their method of using MKMODEL to pooled adult data might have some 
drawbacks as it loses some between-subject variability. Furthermore, children 
with head injuries and ventricular drains also had a disrupted BBB 
(Kawamata et al. 2007, Leonardo and Pennypacker 2009).  
 
Van der Marel and coworkers (2003a) studied paracetamol CSF concentrations 
in 41 children aged 1 week – 18 years. The children were given rectal 
paracetamol 32.3 mg/kg before the placement or revision of a ventriculo-
peritoneal shunt or the insertion of an external ventricular drain.  The median 
(25-75th percentile) sampling time was 133 min (33 – 202 min) and CSF 
paracetamol concentrations ranged between 0.0 – 21.0 mg/l. BBB permeation 
was found to be size- but not age-related and the plasma to CSF equilibration 
half-time was estimated to be 0.9, 1, 1.4, 1.6 and 1.93 h in a neonate (3.5 kg), 1-
year-old child (10 kg), 5-year-old child (20 kg), 10-year-old child (30 kg) and 
an adult (70 kg), respectively. The standardized (to 70 kg) plasma to CSF teq 
1.93 h (CV 43%) was similar to that in adults (2.1 h) (Bannwarth et al. 1992), 
but higher than in the previous study by Anderson et al (0.72 h) (1998).A 
possible explanation to this difference is that children in the previous study 
(Anderson et al. 1998) had head injuries and a disrupted BBB.  
 
Allegaert and coworkers sketched the time course of paracetamol 
concentrations in the CSF in two neonates with ventricular drains (Allegaert et 
al. 2004b, Allegaert and Devlieger 2005). In the most recent study, Kozer and 
coworkers (Kozer et al. 2007) attempted to correlate CSF paracetamol 
concentrations with antipyretic action in 31 febrile infants aged less than one 
year. They sampled the CSF 30 minutes to 4 hours after variable doses of oral 
acetaminophen (mean 14.1 mg/kg), as the mean decrease in body temperature 
was 1.2ºC. The authors found CSF paracetamol 9.9 ± 5 mg/l, with no 
differences between boys and girls or between children with and without 
meningitis. The authors found that body temperature decrement was 
correlated with time and paracetamol concentrations in the CSF.  
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Table 9. Main results of previous studies on concentrations of NSAIDs and 
paracetamol in the CSF 
 
 patients dosage sampling 
times 
mean 
Cmax(CSF) 
tmax 
(CSF) 
indomethacin 
(Bannwarth et 
al. 1990) 
n= 52 
24–76y 
im 50mg 
(0.72 kg/mg) 
0.5–12 h 5 μg/l 1 h 
ibuprofen 
(Bannwarth et 
al. 1995) 
n= 46 
25–88y 
po 800mg 
(11.4 mg/kg) 
0.5–8 h R(-) 168 μg/l 
S(+) 315 μg/l 
3 h 
ketorolac 
(Rice et al. 
1993) 
n=29 
22–71 y 
im 90mg 
(1.2 mg/kg) 
1–4.5 h 4 μg/l 2 h 
paracetamol 
(Bannwarth et 
al. 1992) 
n=43 
31–73 y 
iv 1g 
(14 mg/kg) 
0.3–12 h 6 mg/l 2 h 
paracetamol 
(Moreau et al. 
1993) 
n=12 
77 ± 7 y 
iv 1g 
(15 mg/kg) 
 
0.5–6 h 8 mg/l 3 h 
paracetamol 
(Anderson et al. 
1998) 
n=9 
5 months – 
12 y 
po 40 mg/kg 
 
0–10 h 20 mg/l 2.5 h 
paracetamol 
(van der Marel et 
al. 2003a) 
n=41 
1 week – 18 
y 
rectal 32.3 
mg/kg 
0–12 h 21 mg/l 2 h 
paracetamol 
(Kozer et al. 
2007) 
n=31 
1 week – 9 
months 
po 8-22 mg/kg 0.6–4 h 12 mg/l 3 h 
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3 Aims of the study 
NSAIDs and paracetamol are analgesic, antipyretic anti-inflammatory drugs 
commonly used in children. They exert clinically important actions in the 
CNS. However, CNS penetration of NSAIDs has not been established in 
children. Therefore, the present study was designed to evaluate CNS 
penetration of NSAIDs and paracetamol in healthy children. Moreover, an 
attempt was made to evaluate the analgesic plasma concentrations of 
ibuprofen and diclofenac in children. 
 
The primary aim of the present study was to: 
 evaluate the rate and extent of the CSF penetration of indomethacin (I), 
ibuprofen (II), ketorolac (III), diclofenac (IV) and paracetamol (V) in 
healthy children.  
 
The secondary aims were to  
 evaluate the effect of demographic parameters on the CSF penetration 
of non-opioid analgesics (I-V) 
 describe the pain relief of ibuprofen (II) and diclofenac (IV) after 
inguinal surgery with spinal anaesthesia in children. 
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4 Materials and methods 
This open-label prospective study was conducted in five consecutive parts (I, 
II, III, IV, V) at the Kuopio University Hospital in November 2004 – June 2006. 
The patients were 160 children who were scheduled for elective subumbilical 
surgery with spinal anaesthesia and were to receive NSAIDs or paracetamol 
for postoperative pain. 
 
The study protocol was approved by the research ethics committee of the 
Hospital District of Northern Savo (No. 120/2004). The Finnish National 
Agency for Medicines was notified (No. 161/2004); the trial was recorded in 
the EudraCT database (No. 2004-001702-27) and conducted in accordance with 
the principles of the latest revision of the Declaration of Helsinki (WMA). 
Written, informed consent was obtained from the parents or legal guardians, 
and assent from the child. 
 
 
4.1 PATIENTS 
 
The inclusion criteria for the study were 1) age 3 months – 12 years, 2) surgery 
in the lower part of the body, planned to be performed under spinal 
anaesthesia, 3) surgery where NSAIDs or paracetamol were planned to be 
used as preventive pain medication, 4) American Society of Anesthesiologist 
(ASA) physical status I-II, and 5) informed written consent from parents and 
assent from the child. 
 
The exclusion criteria for the study were 1) ASA-physical status 3 or above, 2) 
contraindication to spinal anaesthesia, such as skin infection at the lower back, 
distinct anatomy of the back, increased intracranial pressure, allergy to local 
anaesthetics, 3) contraindication to NSAIDs or paracetamol, such as allergy to 
NSAIDs or paracetamol or any excipients, gastrointestinal ulcer, 
acetylsalicylic-sensitive asthma, hepatic, renal or cardiac insufficiency, 
hypovolemia, bleeding disorder, surgery with a significant risk of 
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haemorrhage, and 4) other reason that the researcher considered to be a 
contraindication. 
 
Altogether 169 children were found eligible for the study. The parents of 7 
children refused consent since they did not want any additional stress for their 
child. Two children were excluded from the study because their operations 
were postponed for administrative reasons. Therefore, 160 children were 
included in the study. Patient baseline characteristics are presented in Tables 
10-11. 
 
 
 
 
Table 10. Patient characteristics (range (median) or number of patients) 
 
 Age 
(months) 
Weight 
(kg) 
Height 
(cm) 
Gender 
(boys/ girls) 
Indomethacin (I) 4-144 (45) 7-48 (15) 63-165 (98) 23 / 8 
Ibuprofen (II) 3-149 (40) 6-54 (15) 54-154 (101) 25/11 
Ketorolac (III) 3-134 (46) 6-49 (15) 59-159 (100) 17/13 
Diclofenac (IV) 3-153 (56) 6-60 (21) 60-169 (111) 24/7 
Paracetamol (V) 3-153 (55) 7-69 (20) 60-160 (108) 19/13 
 
 
 
 
Table 11. Surgical operations (number of patients) 
 
 Hernio-
tomy 
Orchido-
pexy 
Circum-
cision 
Cysto-
scopy 
Ortho-
paedic 
operation 
Other 
Indomethacin (I) 15 2 2 1 6 5 
Ibuprofen (II) 19 1 1 2 6 7 
Ketorolac (III) 10 4 - 2 9 5 
Diclofenac (IV) 8 5 4 6 5 3 
Paracetamol (IV) 11 - 1 10 5 5 
Total 63 12 8 21 31 25 
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4.2 CLINICAL PROTOCOL 
 
Preoperative care 
 
Local anaesthetic patches (eutectic mixture of lidocaine and prilocaine, EMLA, 
Astrazeneca Oy, Espoo, Finland) were placed in the dorsal hands and the back 
to ease punctures, and an intravenous line was placed preoperatively. In 
children older than 6 months, a standard buccal premedication was used, with 
midazolam (0.375 mg/kg up to 7.5 mg, Midazolam Hameln 5 mg/ml, Hameln 
Pharmaceuticals Gmbh, Hameln, Germany) and ketamine (1.25 mg/kg up to 
25 mg, Ketalar 50mg/ml, Pfizer Oy, Espoo, Finland). 
 
The study drugs 
 
A body weight-based dose of the study drug was given preoperatively, 5 
minutes – 22 hours before anaesthesia. The drugs were given as an 
intravenous injection over 5-10 minutes with a volumetric infusion pump. The 
study drugs were: 
I:  indomethacin 0.35 mg/kg (Confortid 50mg/ml, lot no. 547397-2, 
exp. date 05-2006, Dumex-Alpharma A/S, Copenhagen, Denmark), 
diluted in 20 ml normal saline (Natriumklorid Braun 9 mg/ml. 
B.Braun Melsungen AG, Melsungen, Germany). 
II:  ibuprofen 10 mg/kg (Ibuprof von ct Amp. 133 mg/ml, lot no. 
F26775, exp. date 07/2008, ct-Arzneimittel Gmbh, Berlin, 
Germany), diluted in 20 ml normal saline. 
III:  ketorolac 0.5 mg/kg (Toradol 30 mg/ml, lot no. B1889, exp. date 
10/2006, Roche Oy, Espoo, Finland), diluted in 20 ml normal saline. 
IV:  diclofenac 1 mg/kg (Voltaren 25 mg/ml, lot no. S0258, exp. date 
05/2007, Novartis Finland Oy, Espoo, Finland), diluted in buffered 
solution. Normal saline 20 ml was buffered with NaHCO3 7.5%  
0.5 ml (Natriumbicarbonate Braun 75 mg/ml, Braun Medical Oy, 
Helsinki, Finland). 
V:  paracetamol 15 mg/kg (Perfalgan 10 mg/ml, lot no. 5H00568, exp. 
date 08/2007, Bristol-Myers Squibb AB, Bromma, Sweden).  
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CSF and blood sampling 
 
One paired CSF and blood sample was collected from each study patient at 5 
minutes to 22 hours after drug injection. Lumbar puncture was performed in 
the lateral decubitus position in the midline at L3-4 with a Quincke G25-27 
needle. Cerebrospinal fluid 1 ml was aspirated for a sample, and thereafter 
local anaesthetic was injected. Within 5 minutes, another intravenous catheter 
was placed and a blood sample (3 ml) was collected. The intravenous catheter 
was placed in a different limb from that used for the drug injection. 
 
Perioperative care 
 
Before lumbar puncture, the children were sedated with midazolam, 
thiopental (Pentothal Natrium, Abbott Scandinavia AB, Solna, Sweden) and 
propofol (Propofol Fresenius Kabi, Fresenius Kabi AB, Uppsala, Sweden). The 
most commonly used agent for spinal anaesthesia was plain isobaric 
levobupivacaine 5 mg/ml (Chirocaine, Abbott Scandinavia AB, Solna, 
Sweden). The levobupivacaine dose was 0.4 mg/kg in children with body 
weight less than 16 kg, 0.3 mg/kg in those with body weight 16-40 kg, and 0.25 
mg/kg (up to 15 mg) in those with body weight more than 40 kg. Intravenous 
fluids were given based on clinical needs at the discretion of the attending 
anaesthetist. The children were given oxygen, N2O and air via a face mask. 
During anaesthesia, additional doses of intravenous fentanyl were given when 
clinically needed at the discretion of the attending anaesthetist. 
 
Postoperative care 
 
After surgery, the children were transferred to the post-anaesthesia care unit 
(PACU). The vital signs, pain and adverse effects (not classified whether drug-
related or not) were monitored by the study nurses and the researchers. For 
postoperative pain, the children received paracetamol intravenously 15 mg/kg 
and ketoprofen intravenously 1 mg/kg (Orudis 50 mg/ml, Aventis Pharma Oy, 
Helsinki, Finland), at the discretion of the anaesthetist. For rescue analgesia, 
children in pain (pain score > 3 at rest and/or >5 on a numeric rating scale of 0-
10) were given intravenous fentanyl 1 µg/kg (Fentanyl 50 µg/ml B.Braun 
Medical oy, Espoo, Finland) or oxycodone 0.05 mg/kg (Oxanest 10mg/ml, Oy 
Leiras, Helsinki, Finland). Some children, who had undergone a major 
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operation had continuous epidural opioid - local anaesthetic - epinephrine 
infusion. Follow-up after discharge from the PACU was arranged according to 
normal clinical practice. 
 
Postoperative blood sampling (II, IV) 
 
Postoperative pain was monitored more closely in a subgroup of children in 
studies II and IV. Children who had undergone herniotomy with spinal 
anaesthesia and sedation, and received no other analgesics but the bolus dose 
of study compounds ibuprofen or diclofenac, were included in the subgroup. 
Children who had received paracetamol, additional doses of NSAIDs, or 
opioids, were not included in the group. In study II, the protocol was 
amended after 31 children were included in the study, and therefore samples 
were collected from only five children. 
 
Pain was assessed in the PACU by the researchers and trained study nurses 
every 15 minutes at rest and with a light pressure (20 Newton) on the wound 
area. Assessment was made by using an 11-point numeric rating scale (0 = no 
pain, 10 = worst possible pain). The report of the child (when available) and 
the assessment of the observer were both recorded. When the child first 
expressed or was assessed to have wound pain, a second blood sample (3 ml) 
was obtained for the estimation of analgesic plasma concentration of 
ibuprofen or diclofenac. Thereafter the children received intravenous 
paracetamol 15 mg/kg and ketoprofen 1 mg/kg, and opioid for rescue 
analgesics if needed. 
 
 
4.3 DRUG ASSAYS 
 
Indomethacin (I), ibuprofen (II), ketorolac (III) and diclofenac (IV) 
concentrations in plasma, protein-free plasma and CSF were measured by the 
gas chromatography-mass spectrometry method. Protein free plasma was 
obtained by ultra-filtration. Paracetamol (V) concentrations in the plasma and 
CSF samples were determined by using fluorescence polarization 
immunoassay technology (TDxFLx; Abbott Laboratories, Abbott Park, Illinois, 
USA). The methods are described in detail in publications I – V. The accuracy, 
recovery and intra-day precision are reported in publications I-V.  
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4.4 STATISTICS 
 
No formal sample size calculation was performed, but a sample of 30 children 
in each group was considered to provide sufficient information on the CSF 
permeation of each drug. Data were entered and analyzed with the Statistical 
Package for Social Sciences (SPSS Software versions 11.5, 13.0 and 14.0 for 
Windows, SPSS Inc., Chicago, USA). The results are presented as number of 
cases or median with range. The drug concentrations in paired CSF and 
plasma samples are presented for each individual. The trend line on CSF 
concentrations versus time plot was generated by applying locally weighted 
smooth regression (kernel function: Epanechnikov and points to fit: 50%). 
 
In a post hoc analysis, the effect of sex, age, height, weight and body surface 
area (estimated by the DuBois method; DuBois and DuBois 1916) on drug 
concentrations in the CSF was studied with polynomial regression. First the 
effect of time was estimated by fitting a cubic regression curve, and then the 
effect of sex, age, height, weight and body surface area were studied 
separately with polynomial regression. The predictors were: time, time2, time3, 
and sex, age, height, weight or body surface area. The dependent variable was 
drug concentration in the CSF. A p-value of 0.05 was considered as the limit of 
statistical significance. 
 
 
4.5 CALCULATIONS ON PROTEIN BINDING OF NSAIDS IN THE CSF 
 
Non-protein-bound (free) drug concentrations were measured in plasma, and 
total drug concentrations were measured in plasma and the CSF. However, 
protein binding was not determined in the CSF, and therefore calculations on 
protein binding of NSAIDs in the CSF are presented. The calculations are 
based on binding equations of NSAID binding to albumin in plasma (Honoré 
and Brodersen 1984, Borgå and Borgå 1997, Deschamps-Labat et al. 1997, 
Yamasaki et al. 2000) (Table 12-15). The free drug concentration in the CSF is 
assumed to be equal to the free drug concentration in plasma, and the median 
of that is chosen. The CSF albumin concentration is assumed to be 2.3 x 10-6 M 
(Illi et al. 1983), and the molar masses are presented in Table 7. 
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Table 12. The stoichiometric binding equation by Honoré and Brodersen 
(Honoré and Brodersen 1984), and the values used in the calculations 
 
 
 
 
rx = number of moles of drug bound per mole of protein 
K1, K2…KN = stoichiometric binding constants 
x = molar concentration of free drug 
Indomethacin N=7 
K1 = 250 000 
K2 = 100 000 
K3 = 55 000 
K4 = 32 000 
K5 = 18 000 
K6 = 9 500 
K7 = 3 900 
x = 1.3966 x 10-9 
Ibuprofen N=8 
K1 = 80 000 
K2 = 35 000 
K3 = 20 000 
K4 = 13 000 
K5 = 8 000 
K6 = 5 500 
K7 = 2 900 
K8 = 1 300 
x = 0.3495 x10-6 
Diclofenac N=7  
K1 = 550 000 
K2 = 190 000 
K3 = 87 000 
K4 = 42 000 
K5 = 22 000 
K6 = 11 500 
K7 = 4 300 
x = 2.7027 x 10-9 
 
 
 
 
Table 13. Model by Borgå and Borgå (Borgå and Borgå 1997) with high and 
low affinity binding sites, and the values used in the calculations 
 
 
 
 
Cb = concentration of bound drug 
Alb = albumin concentration 
Cu = concentration of free drug 
N1, N2= number of binding sites for high and low affinity sites 
K1, K2 = dissociation constants for high and low affinity binding 
sites 
 
 
 
 
Diclofenac  
N1= 1.80 
K1 = 2.57 x 10-6 
K2 = 8.50 
K2= 108 x 10-6 
Alb = 2.3 x 10-6 
Cu = 2.7027 x 10-9 
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Table 14. Model by Deschamps-Labat and coworkers with two saturable 
binding sites (Deschamps-Labat et al. 1997), and the values used in the 
calculations 
 
 
 
 
r = number of moles of drug bound per mole of protein 
n1 = number of binding sites per mole of albumin for site I 
K1 = association constant for site I 
n2 = number of binding sites per mole of albumin for site II 
K2 = association constant for site II 
F = molar concentration of free drug 
 
 
 
 
Ibuprofen 
n1=0.98 
K1=434.56 x 103 
n2= 5.12 
K2= 8.59 x 103 
F=0.3495 x10-6 
 
 
 
 
Table 15. Model by Yamasaki et al. (Yamasaki et al. 2000) with two binding 
sites, high and low affinity, and the values used in the calculations 
 
 
 
 
r = number of moles of drug bound per mole of protein 
Kh, Kl = association constants for high and low affinity binding sites 
nh, nl = number of binding sites for high and low affinity binding sites 
Cf = molar concentration of free drug 
Ibuprofen 
Kh = 3.3 x 106  
Kl = 5.5 x 104  
nh = 1.0 
nl = 4.8  
Cf = 0.3495 x10-6 
Diclofenac 
Kh = 3.3 x 106  
Kl = 5.4 x 104  
nh = 1.0  
nl = 4.9  
Cf = 2.7027 x10-9 
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4.6 PROTOCOL DEVIATIONS 
 
There were five major protocol deviations in the study drug administration. In 
study III, one child received ketorolac 0.35 mg/kg subcutaneously, instead of 
0.5 mg/kg intravenously, due to extravasation of the injection. In study V, one 
child was given paracetamol 20 mg/kg and one 12.5 mg/kg instead of 15 
mg/kg, and two children had paracetamol infusion over 30 and 40 minutes 
instead of 5-10 minutes. These cases were excluded. 
 
There were 17 deviations in the CSF samples (Table 16). Four CSF samples 
were reddish, indicating blood contamination; these were excluded. Thirteen 
CSF samples had the drug concentrations below the limit of quantitation; for 
statistical analysis they were replaced with the value calculated as limit of 
quantitation/2, as indicated in Figures 12-16. The lower limit of quantification 
of indomethacin, ibuprofen, ketorolac, diclofenac and paracetamol assay was 
0.1 µg/l, 4.0 µg/l, 0.1 µg/l, 0.1 µg/l and 1.0 mg/l, respectively. 
 
 
 
 
Table 16. Protocol deviations in the study 
 
 
Major deviation in 
the study drug 
administration 
CSF sample was 
reddish 
CSF samples with 
drug 
concentration 
below the limit of 
quantitation 
Indomethacin (I) 0 2 2 
Ibuprofen (II) 0 0 0 
Ketorolac (III) 1 1 8 
Diclofenac (IV) 0 0 2 
Paracetamol (V) 4 1 1 
Total 5 4 13 
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5 RESULTS 
5.1 DRUG CONCENTRATIONS IN THE CSF 
 
The range and median of drug concentrations in the CSF, plasma, and protein-
free plasma, and the ratios of concentrations in those three compartments are 
shown in Table 17 and Figures 12-16.  
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Indomethacin (I) 
 
Indomethacin was detected in 27 out of 29 CSF samples collected at 14 
minutes to 3.75 hours after indomethacin 0.35 mg/kg iv. Two samples 
collected at 14 and 19 minutes had indomethacin below the limit of 
quantitation 0.1 µg/l. Indomethacin concentrations in 27 CSF samples ranged 
between 0.2 and 5.0 µg/l, with a median of 1.4 µg/l, and the highest 
concentrations were detected at 1 hour (Figure 12). 
 
 
 
 
Figure 12. Indomethacin concentrations in the CSF in 29 children after 
indomethacin 0.35 mg/kg iv 
62 
Ibuprofen (II) 
 
Ibuprofen was detected in all 36 CSF samples collected at 10 minutes to 8 
hours after ibuprofen 10 mg/kg iv. Ibuprofen concentrations in the CSF ranged 
between 15 and 541 µg/l (median 182 µg/l) and the highest concentrations 
were detected at 1 hour (Figure 13).  
 
 
 
 
Figure 13. Ibuprofen concentrations in the CSF in 36 children after ibuprofen 
10 mg/kg iv and locally weighted smooth regression trend line 
 
0 120 180 24060 300 360 420 480 
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Ketorolac (III) 
 
Ketorolac was detected in 20 out of 28 CSF samples collected at 13 minutes to 
5.5 hours after ketorolac 0.5 mg/kg iv. Ketorolac concentrations were below 
the limit of quantitation, 0.1 µg/l, in eight samples collected at 11-19 minutes 
and at 1-6 hours after the drug administration. Ketorolac concentrations in the 
CSF ranged between 0.2 and 3.0 µg/l (median 0.5 µg/l), and the highest 
concentrations were detected at 1 hour (Figure 14). 
 
 
 
 
Figure 14. Ketorolac concentrations in the CSF in 28 children after ketorolac 
0.5 mg/kg iv and locally weighted smooth regression trend line 
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Diclofenac (IV) 
 
Diclofenac was detected in 29 out of 31 CSF samples at 5 minutes to 5.5 hours 
after diclofenac 1 mg/kg iv. Diclofenac concentration in the CSF was below the 
limit of quantitation 0.1 µg/l in two samples collected at 22 hours. The 
concentrations in the CSF were 0.1–4.7 µg/l (median 1.2 µg/l), and the highest 
concentrations were detected at 1 hour (Figure 15). 
 
 
 
 
 
Figure 15. Diclofenac concentrations in the CSF in 29 children after diclofenac 
1 mg/kg iv and locally weighted smooth regression trend line 
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Paracetamol (V) 
 
Paracetamol was detected in 26 out of 27 CSF samples collected at 6 minutes 
to 5 hours after paracetamol 15 mg/kg iv. One sample at 5 minutes had a 
paracetamol concentration below the limit of quantitation of 1.0 mg/l. 
Paracetamol concentrations in the CSF ranged between 1.3 and 18.0 mg/l with 
the median of 7.2 mg/l, and the highest concentrations were detected at 1-2 
hours (Figure 16).  
 
 
 
 
Figure 16. Paracetamol concentrations in the CSF in 27 children after 
paracetamol 15 mg/kg iv and locally weighted smooth regression trend line 
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5.2 DRUG CONCENTRATIONS IN THE CSF AND PATIENT CHARACTERISTICS 
 
The polynomial regression curves fit to the data on ibuprofen, diclofenac and 
paracetamol at the time ranges of 10-469, 5-333 and 5-308 minutes, 
respectively (Figure 17). For indomethacin, the effect of time was estimated by 
fitting a linear curve (Figure 17). An attempt to fit a curve to the data on 
ketorolac was unsuccessful, and therefore analyses were not performed. 
Indomethacin and diclofenac concentrations in the CSF were related to age, 
height, weight and body surface area of the children. Younger and smaller 
children had higher drug concentrations in the CSF than did older and taller 
children. Ibuprofen concentrations in the CSF were not related to sex, age, 
height, weight or body surface area. Paracetamol CSF concentrations were 
related to sex: girls had higher concentrations of paracetamol in the CSF than 
boys. The p-values are shown in Table 18.  
 
 
 
Figure 17. The polynomial regression curves for data on indomethacin, 
ibuprofen, diclofenac and paracetamol, respectively 
 
 
Table 18. The relation of drug CSF concentrations and patient characteristics. 
P-values of the regression analyses 
 
 sex age height weight body 
surface area 
indomethacina ns 0.006 0.01 0.041 0.019 
ibuprofen ns ns ns ns ns 
diclofenac ns 0.014 0.002 0.033 0.010 
ketorolacb      
paracetamol 0.009 ns ns ns ns 
 
a. the effect of time was estimated with a linear instead of a cubic curve 
b. no analyses, because the cubic curve did not fit the data 
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5.3 KETOROLAC CONCENTRATIONS IN PLASMA SAMPLES (III) 
 
Ketorolac concentrations in plasma ranged between 449 and 4831 µg/l (2603 
µg/l). Protein free plasma concentrations ranged between 2.0 and 31.9 µg/l (9.1 
µg/l). Ketorolac concentrations in the CSF, protein free plasma (unbound) and 
total plasma in each patient are shown in Table 19. This table contains the 
correct data. In original publication III, the data in the last column of Table I 
are incorrect.  
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5.4 CALCULATIONS ON PROTEIN BINDING IN THE CSF 
 
The models by Honoré and Brodersen (1984), Borgå and Borgå (1997), 
Deschamps-Labat et al. (1997) and Yamasaki et al. (2000) were applied. The 
results of calculations are presented in Table 20. According to the models, 
indomethacin was 37%, ibuprofen 15-49%, and diclofenac 56-89% bound to 
albumin in the CSF. 
 
 
 
 
Table 20. Calculations of protein binding of NSAIDs in the CSF 
 
 Assumed free 
drug in the 
CSF (µg/l) 
Calculated 
total drug in 
the CSF (µg/l) 
Calculated 
bound drug in 
the CSF 
Reference 
Indomethacin 0.5 0.78 37% 
(Honoré and 
Brodersen 1984) 
Ibuprofen 72 140 49% 
(Deschamps-Labat 
et al. 1997) 
Ibuprofen 72 85 15% 
(Honoré and 
Brodersen 1984) 
Ibuprofen 72 125 43% 
(Yamasaki et al. 
2000) 
Diclofenac 0.8 1.8 56% 
(Honoré and 
Brodersen 1984) 
Diclofenac 0.8 2.2 64% 
(Borgå and Borgå 
1997) 
Diclofenac 0.8 7.3 89% 
(Yamasaki et al. 
2000) 
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5.5 PLASMA CONCENTRATIONS AT ONSET OF PAIN AFTER SURGERY 
 
Ibuprofen (II) 
 
Three samples were collected as defined in the protocol (Table 21). Pain 
occurred at 266, 186, 222 minutes after ibuprofen administration, at 97, 129, 
208 minutes after spinal anaesthesia and at 57, 116, 171 minutes after the end 
of surgery. The pain intensity in NRS (0-10, at rest/with light (20N) pressure 
on the wound) was assessed to be 1/3, 1/4 and 2/3. Ibuprofen concentrations in 
plasma and protein free plasma at the onset of pain were 10 x103, 25 x103, 11 
x103 µg/l and 15, 26, 32 µg/l, respectively (Figure 18). 
 
 
 
 
Table 21. Ibuprofen concentrations in plasma at onset of pain after surgery 
 
 
 
onset of pain after 
(min) 
ibuprofen concentration 
(μg/l) 
patient 
number 
operation 
ibuprof 
inj 
spinal 
anaesth 
surgery plasma 
free 
plasma 
  33 * herniotomy 213 201 169 21 x103 20 
  34 herniotomy 266 97 57 10 x103 15 
  35 ** herniotomy 189 175 138 25 x103 157 
  36 herniotomy 186 129 106 25 x103 26 
  37 herniotomy 222 208 171 11 x103 32 
 
* The sample was collected 50 minutes after pain occurrence, and was 
therefore excluded 
** The patient had received fentanyl 10 µg after surgery, and was therefore 
excluded 
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Figure 18. Ibuprofen concentrations in plasma (x 103 µg/l). Black circles 
represent samples collected at onset of pain after inguinal surgery and spinal 
anaesthesia. Grey squares represent other plasma samples. 
 
 
73 
Diclofenac (IV) 
 
Eight samples were collected as defined in the protocol (Table 22). Pain 
occurred at 97-316 (183) minutes after diclofenac administration, at 91-296 
(134) minutes after spinal anaesthesia and at 20-272 (98) minutes after the end 
of surgery. Pain intensity at the onset of pain in NRS was assessed to be 0-3/10 
at rest and 2-6/10 with light (20N) pressure on the wound. Diclofenac 
concentrations in plasma in seven samples ranged between 70 and 272 
(median 104) µg/l, and diclofenac was not detected in one sample (Figure 19).  
 
 
 
 
Table 22. Diclofenac concentrations in plasma at onset of pain after surgery 
 
  onset of pain after (min) ibuprofen concentration 
(μg/l) 
patient 
number 
operation ibuprof 
inj 
spinal 
anaesth 
surgery plasma free plasma 
   1 orchidopexy 194 180 106 102 ND 
   3 * circumcision 322 200 175 ND ND 
   7 * orthopaedic 472 142 87 ND ND 
  12 * orthopaedic 272 203 169 75 ND 
  15 * orthopaedic 408 217 159 ND ND 
  16 * orthopecid 240 180 145 133 0.4 
  17 herniotomy 295 125 94 ND ND 
  19 herniotomy 108 98 50 272 0.6 
  25 orchidopexy 316 296 271 104 0.7 
  28 herniotomy 97 91 20 163 ND 
  29 herniotomy 142 112 77 124 ND 
  30 herniotomy 160 143 102 94 ND 
  31 orchidopexy 130 225 163 70 ND 
 
* The operation was not herniotomy or orhciopexy, and was therefore 
excluded 
ND none detected, concentration was below the lower limit of quantification 
(58 µg/l for plasma and 0.1 µg/l for protein-free plasma) 
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Figure 19. Diclofenac concentrations in plasma (µg/l). Black circles represent 
samples collected at onset of pain after inguinal surgery and spinal 
anaesthesia. Grey squares represent other plasma samples. One sample at 13 
minutes with concentration 4232 µg/l, and two samples at 22 hours with 
concentration below the limit of quantification are not shown. 
 
 
 
 
5.6 THE ADVERSE EFFECTS 
 
A total of 41 adverse effects occurred in 40 out of 160 patients (Table 23). CNS 
adverse effects, agitation and anxiety, were reported in 19 children. 
Gastrointestinal adverse effects, nausea, vomiting and abdominal pain, 
occurred in 16 children. No serious or unexpected adverse effects occurred. 
The likelihood of the study drugs causing the reaction was not rated. 
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6 Discussion 
6.1 GENERAL DISCUSSION 
 
6.1.1 Study population 
 
NSAID permeation in the CNS has previously been studied in adults 
(Bannwarth et al. 1990, 1992, 1995, Rice et al. 1993) but there are few studies in 
children. Paracetamol concentrations in the CSF have been studied in children 
with a disturbed BBB (Anderson et al. 1998, van der Marel et al. 2003a), and 
ketoprofen concentrations in the CSF in healthy children (Kokki et al. 2002, 
Mannila et al. 2006). Therefore, the present study evaluated the CSF 
concentrations of various NSAIDs and paracetamol in healthy children. CSF 
samples were collected during lumbar puncture for spinal anaesthesia. None 
of the patients had head trauma, CNS infections or other diseases of the CNS 
that may affect the BBB permeation. The children had elective surgery, and 
they were not suffering from major trauma or systemic inflammatory or 
infectious process. Therefore, it seems that the patients had a non-disturbed 
BBB, and thus the results should be soundly based. 
 
6.1.2 Study design 
 
In the present study, intravenous dosing of NSAIDs and paracetamol was 
used to eliminate the effect of absorption and first-pass metabolism. However, 
only one CSF sample was collected per study patient. Samples were collected 
at induction of spinal anaesthesia, so it was possible to collect only one CSF 
sample per patient. Multiple samples at different time points would have 
given more information about the CNS kinetics of NSAIDs and paracetamol in 
children. 
 
There are some important limitations when CSF concentrations are used to 
evaluate target concentrations in the brain (de Lange and Danhof 2002). Brains 
consist of multiple compartments (Figure 7), and many factors affect the 
transport of drugs between the compartments. Different drugs have different 
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effect compartments in the brain, such as the intracellular fluid (for anti-HIV 
drugs, cytostatics, NSAIDs) and the extracellular fluid (for antibiotics). 
Biological barriers such as the ependyma and the BBB are active and metabolic 
barriers, which limit the transport of drugs between different compartments; 
therefore, concentrations measured in one compartment do not necessarily 
correlate with those in other compartments. Furthermore, the measured 
lumbar CSF drug concentrations may differ from brain ventricular CSF 
concentrations. Moreover, some regional differences may occur as a result of 
physiological and pathological conditions. It seems that lumbar CSF drug 
concentrations (measured in the present study) are similar to thoracic CSF 
drug concentrations, because of the constant flow of the CSF and the short 
distance involved. In addition, the spinal targets of NSAIDs are in close 
contact with thoracic CSF (Svensson and Yaksh 2002), and therefore lumbar 
CSF concentrations can be considered relevant for the spinal action of 
NSAIDs. 
 
6.1.3 Analytical methods 
 
In the present study, NSAID concentrations in the CSF were measured by a 
highly selective and sensitive gas chromatography-mass spectrometry 
method. Previously the sensitivity of the assay has been the limiting factor 
when NSAID CSF permeation has been studied in children (Kokki et al. 2002, 
Mannila et al. 2006). The current method was highly sensitive, and we were 
able to quantify the concentrations of NSAIDs in 113 out of 125 CSF samples 
(in I-IV). The validity of the method was partially studied according to FDA 
guideline for bioanalytical method validation (FDA 2001).  
 
The precision of the indomethacin assay (I) was good for indomethacin 
concentrations 0.8 – 15 µg/l (CV 3-15%), but poorer for concentrations in the 
lower range of the method (0.1 µg/l) (CV 34%). Indomethacin concentrations 
in plasma were above 90 µg/l, and in the CSF mostly above 0.8 µg/l (with five 
samples below this). Therefore the results of indomethacin in plasma and the 
CSF can be considered precise. However, indomethacin protein free plasma 
concentrations were in the lower range of the method, ranging between 0.3 
and 0.8 µg/l. Therefore the values of protein free plasma indomethacin should 
be interpreted with caution. However, despite problems with the precision, 
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the accuracy was good (98 – 122%) also in the lower range of the method The 
precision of the other assays used, was good (CV <20%). 
 
In the present study, the NSAIDs ketorolac and ibuprofen were administered 
as racemic drugs, which are used in normal clinical practice. It seems that only 
the S-forms of ibuprofen and ketorolac have analgesic actions (Malmberg and 
Yaksh 1992, Mroszczak et al. 1996, Yaksh et al. 2001), so it would have been 
interesting to measure the concentrations of S- and R-isomers in the CSF. Such 
analysis would have been possible, but the sensitivity would have been 
considerable poorer (100-1000 times lower, due the use of different ionization 
method). Poorer sensitivity would have been a problem especially with 
ketorolac, because ketorolac concentrations in the CSF were low and the 
amount of CSF available for analysis was limited. Therefore the concentrations 
of racemic drugs, instead of both isomers, were analyzed. 
 
6.1.4 Statistical methods 
 
Polynomial regression analysis was used to evaluate the effect of demographic 
parameters on the CSF penetration of the drugs. This method has many 
limitations in the situation and it could not be used for the data on ketorolac. 
Pharmacokinetic methods, non-linear regression or the use of smoothed 
splines would have been better for this evaluation. However, this study was 
not designed to evaluate the effect of demographic parameters, and a different 
study design with stratification or randomization would have improved such 
an evaluation. 
 
6.1.5 Ethical aspects 
 
The importance of paediatric studies in pharmacology has been noted in 
recent years (Caldwell et al. 2004). The World Health Organization (WHO) 
launched an initiative in 2007 to make drugs available for children. A new 
paediatric regulation entered into force on 26th January 2007 in the European 
Union, requiring new drugs to be studied in children, and offers extended 
patents for old drugs if they are studied in children (The European Parliament 
and the Council 2006). Furthermore, the paediatric subpopulation is discussed 
in document E11 by ICH (International conference on harmonisation of 
technical requirements for registration of pharmaceuticals for human use) 
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(ICH 2000). In the United States of America, the act Best Pharmaceuticals for 
Children promotes paediatric clinical trials (107th Congress of the United 
States of America 2002). 
 
Consent 
 
A paediatric population represents an especially vulnerable subgroup. 
Children are not legally able to provide informed consent for study 
participation, and therefore consent is sought from the parents or legal 
representatives on the child’s behalf. However, children older than 15 years 
are considered mature enough to give consent to a study that is beneficial to 
them, but their legal guardians are also notified. Moreover, children at all ages 
should receive information about the study, according to their capacity to 
understand. Children’s opinions on study participation should be respected 
and therefore written or non-written assent should be obtained whenever a 
child is able to give it. Recently, after this study was conducted, new 
recommendations have been published on paediatric studies and on the 
information to be provided to children (Finpedmed). 
 
In this study, informed written consent was obtained from parents or legal 
representatives of the child. The parents were given explanations about the 
normal anaesthesia method and the study interventions, and the aims of the 
study. They were also provided written information about the study 
(approved by the ethics committee), and given the opportunity to ask 
questions and time to consider participation and to talk with their spouse. If 
the child presented in the hospital the day before surgery, recruitment was 
preformed then. If the child had day-case surgery and presented only in the 
morning, the parent was contacted by phone in the previous afternoon and 
the study protocol was briefly explained, thereby allowing time to consider 
participation; and written consent was asked for in the morning. If the child 
was considered old enough to understand the study interventions, 
information was provided to him/her too and written assent was obtained. 
 
Study interventions 
 
It is considered unethical to recruit healthy volunteers for studies on 
paediatric pharmacology. Furthermore, performing invasive procedures, such 
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as lumbar puncture, involves risks (such as post-dural punction headache, 
back pain, neurological symptoms, infection and subdural haematoma). In 
this study CSF was collected during lumbar puncture, which was indicated 
for spinal anaesthesia and surgery. The volume of CSF sample was 1 ml or 
less, therefore smaller than the volume of intrathecally injected local 
anaesthetic. Therefore, CSF sampling should have had minimal additional 
risks. Moreover, analyses on data collected on spinal anaesthesia in children 
indicate that CSF aspiration does not affect the spread and duration of sensory 
block, or the recovery from spinal anaesthesia in children (Hannu Kokki, 
unpublished observation). Numerous studies indicate that spinal anaesthesia 
is a feasible method also in children (Kokki and Hendolin 1995, Kokki et al. 
2000, Kokki et al. 2004). 
 
In paediatric clinical research, additional pain and distress, such as 
venepuncture for blood samples, should be avoided (ICH 2000, Lötjönen et al. 
2008). In normal practice at the Kuopio University Hospital, an intravenous 
line is placed in healthy children coming to elective surgery in the operation 
room at anaesthesia induction. Parents are not allowed in the operation room, 
since parents have little impact on the performance of a premedicated child at 
induction (Kain et al. 2006, Chundamala et al. 2009, Yip et al. 2009). In this 
study, an intravenous line was placed on the surgical ward or the day-case 
surgery centre playroom, in the presence of the parents. This allowed the 
parents to support their child, as needle insertion causes anxiety and 
sometimes hurts despite the local anaesthetic patch (Cordoni and Cordoni 
2001). The second intravenous catheter was placed in sedated children under 
spinal anaesthesia, most commonly in a dorsal foot vein, after the onset of 
sensory block by spinal anaesthesia, and therefore should not have caused any 
pain or distress to the children. 
 
Pain control 
 
Paediatric postoperative pain management studies are sometimes considered 
unethical (Korpela et al. 1999, Black and Mackersie 2000). In the subpopulation 
of this study, children (n=5 in study II and n=13 in study IV) were provided 
with one bolus dose of preventive pain medication and spinal anaesthesia. 
After surgery as the sensory block was wearing off, pain was monitored every 
15 minutes. When the child was first assessed to have any wound pain, a 
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blood sample was collected; thereafter pain medication was immediately 
continued. The study protocol was considered ethical, because the patients 
were provided with effective pain relief with intravenous paracetamol and 
ketoprofen, and opioid for rescue analgesia, as soon as they showed the first 
symptoms of wound pain. 
 
 
6.2 THE TIME COURSE OF DRUG CONCENTRATIONS IN THE CSF 
 
The CNS permeation of NSAIDs and paracetamol has not been adequately 
described previously. Most previous studies evaluate permeation after 
intramuscular or oral dosing (Table 9). There are only two adult studies after 
intravenous paracetamol (Bannwarth et al. 1992, Moreau et al. 1993) and two 
paediatric studies after intravenous ketoprofen (Kokki et al. 2002, Mannila et 
al. 2006). Therefore, this is the most extensive study on CNS bioavailability 
after intravenous NSAIDs. This study shows that most NSAIDs reached the 
highest concentrations in the CSF at 60 minutes, after which the concentrations 
began to fall. Indomethacin concentrations in the CSF were variable, and rose 
faster than those of other NSAIDs. Paracetamol concentrations in the CSF 
peaked at 1-2 hours. From a clinical perspective, the CNS permeation of 
NSAIDs and paracetamol is rapid. 
 
In previous studies, the peak concentrations of NSAIDs and paracetamol in 
the CSF were observed at 2-3 hours (Table 9) (Bannwarth et al. 1990, 1992, 
1995, Moreau et al. 1993, Rice at al. 1993, Anderson et al. 1998, van der Marel 
et al. 2003a, Kozer at al. 2007), whereas in the present study the peak occurred 
significantly earlier, most commonly at 1 hour. The reason for this is probably 
the different administration routes (Gibb and Anderson 2008): in the previous 
studies the drugs were given by mouth (Bannwarth et al. 1995, Anderson et al. 
1998, Kozer at al. 2007), intramuscularly (Bannwarth et al. 1990, Rice at al. 
1993) or rectally (van der Marel et al. 2003a,), whereas in the present study 
intravenous dosing was used. In the previous studies the drug had to be 
absorbed first, and only then could be distributed in the CSF. Typically the 
absorption of NSAIDs and paracetamol is fast, the peak concentrations in 
plasma occurring 1-2 hours after intramuscular or oral dosing (Forrest et al. 
1982, Davies and Anderson 1997, Gillis and Brogden 1997, Davies 1998), and 
this fits well with the peak in CSF at 2-3 hours. 
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The findings of the present study throw light on the optimal timing of 
preventive analgesic administration. In the present study, NSAIDs and 
paracetamol were given as intravenous injections over 5-10 minutes, and the 
highest drug concentrations in the lumbar CSF were observed 1 hour after 
administration. Based on the assumption that CSF concentrations are more 
closely related to analgesia than plasma concentrations, the optimal time to 
administer preventive intravenous analgesics might be 1 hour before the onset 
of acute pain. The current common clinical practice is to give enteral drugs 
approximately 1-2 hours before anticipated intense pain, and parenteral drugs 
only shortly before or at the onset of pain. It is possible that earlier 
administration of intravenous analgesics would improve pain control on the 
early phase of acute pain (Rømsing et al. 1998, Møiniche et al. 2002, Kehlet et 
al. 2006), because of sufficient CNS concentrations. Previous studies on 
postoperative pain have observed maximal pain relief at 0.5-1 hour after 
intravenous NSAIDs and paracetamol (Rice et al. 1995, Mandema and Stanski 
1996, Granry et al. 1997, Moller et al. 2005, Murat et al. 2005). However, results 
on pre-emptive use of NSAIDs are contradictory (Norman et al. 2001, Kokki 
and Salonen 2002, Ong et al. 2005), and furthermore pre- and perioperative 
administration of NSAIDs is limited by the risk of increased blood loss, and 
renal adverse effects in the case of hypovolemia and hypotension. 
 
 
6.3 COX INHIBITION AT CONCENTRATIONS OF NSAIDS OBSERVED IN THE 
CSF 
 
With the doses used in the present study, NSAID concentrations in the CSF 
are relevant in pain management. The noxious stimulus from the lower part of 
the body is conducted by Aδ- and C-fibres via the dorsal root ganglia to the 
dorsal horn of the spinal cord. The first synapse is in the outer part of the 
dorsal horn, in the substantia gelatinosa, and from there the axons continue 
with the spinothalamic tract up the contralateral ventral surface of the spinal 
cord, through the medulla, pons and the midbrain, to the thalamus. Therefore, 
the synapses and neurons are in close contact with the CSF. Moreover, COX is 
expressed in the spinal cord constitutively, and also in response to a painful 
stimulus (Svensson and Yaksh 2002, Zhu et al. 2003). 
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The issue of sufficient drug concentrations in the CNS is complicated. In the 
present study, CSF pharmacokinetics, instead of pharmacodynamics using an 
effect measure (e.g. pain relief), was studied, and therefore no distinct 
conclusions on this subject can be made. However, some comparisons 
between the results and those of previous studies are presented here. The 
results (IC50 of COX-1 and COX-2 inhibition) from three previous studies 
(Mitchell et al. 1993, Warner et al. 1999, Kato et al. 2001) are summarized in 
Table 2. However, the results are obtained from different study settings, 
which have their advantages and drawbacks (Pairet and van Ryn 1998), and 
the results vary a lot. 
 
Indomethacin IC50 of COX-1 is 3.2 µg/l (Kato et al. 2001), which is in the range 
of the observed CSF indomethacin concentrations (range 0.2 – 5.0 µg/l), so it is 
possible that the observed concentrations yield analgesic actions in the CNS. 
Ibuprofen IC50 for COX-1, according to Mitchell et al. (1993), is twice the 
observed CSF concentrations in the present study. However, in a study by 
Cryer and Feldman (1998), IC50 for ibuprofen in human gastric mucosa was 
140 µg/l, which is in the range of observed ibuprofen concentrations in the 
CSF. This indicates that the observed concentrations in the present study 
might be high enough for COX inhibition as well. For ketorolac, the median of 
observed concentrations in the CSF was ten times higher than its IC50 for COX-
1 (Warner et al. 1999). In previous studies the IC50 for COX-2 of diclofenac was 
7.7 µg/l (Kato et al. 2001) and 0.29 µg/l (Kawai et al. 1998), indicating that the 
observed CSF concentrations, 0.1 – 4.7 µg/l, might be high enough for COX 
inhibition as well. 
 
 
6.4 PROTEIN BINDING AND DRUG CONCENTRATIONS IN THE CSF 
 
Protein binding seems to be a major factor affecting NSAID CNS permeation 
(Parepally 2005). It is believed that the BCSFB allows non-protein-bound (free) 
drug in plasma to reach equilibrium with free drug in the CSF (Figure 20). In 
the present study, some calculations were performed to approximate NSAID 
protein binding in the CSF. It seems that the models are applicable to the 
situation, because the predicted percent bound in the CSF fits fairly well with 
the findings ofprevious study (Müller et al. 1991) and also with the ratio of 
total concentration in CSF to unbound concentration in plasma in the present 
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study. However, applying the equations (Honoré and Brodersen 1984, Borgå 
and Borgå 1997, Deschamps-Labat et al. 1997, Yamasaki et al. 2000) may have 
some drawbacks. The models were built to describe NSAIDs binding to 
albumin in plasma. Here the calculations were extrapolated to the situation in 
the CSF, with albumin concentration less than 0.5% of that in plasma. 
Therefore, the results are rough extrapolations, and should be interpreted with 
caution, and a more detailed model with predictions for individual patients 
was not built. Furthermore, it is possible that protein binding in the CSF is 
more extensive in young children, because the concentration of proteins in the 
CSF is higher in infants than in older children and adults (Biou et al. 2000, 
Wong et al. 2000). 
 
Indomethacin 
 
Indomethacin concentrations in the CSF were three times higher than free 
concentration in the plasma (median 1.4 and 0.5 µg/l, respectively). 
Indomethacin binding to proteins in the CSF may explain this phenomenon. 
Two studies (Honoré and Brodersen 1984, Müller et al. 1991) on the protein 
binding of indomethacin in the CSF suggest 40% binding. However, this 
percentage of binding should lead to a CSF/free plasma ratio of 1.7, whereas 
the median was 3.1 in the present study (range 0.4-15). However, imprecision 
of the analytical method in the range of free plasma indomethacin 
concentrations is a possible explanation to higher CSF/free plasma ratios than 
expected. 
 
Ibuprofen  
 
Ibuprofen concentrations in the CSF were two – three times higher than its 
free plasma concentrations in samples collected after 20-30 minutes (median 
182 and 72 µg/l, respectively). The binding equations (Honoré and Brodersen 
1984, Deschamps-Labat et al. 1997, Yamasaki et al. 2000) suggest 15-49% 
binding in the CSF. Fifty percent binding would result in a CSF to free plasma 
ratio of 2, which is comparable to the observed median of 2.3 in the present 
study. 
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Figure 20. Free ibuprofen in plasma reaches equilibrium with free ibuprofen in 
the CSF 
 
 
Ketorolac 
 
In contrast to indomethacin, ibuprofen and diclofenac, ketorolac 
concentrations in the CSF remained below free plasma concentrations at all 
times (median of the ratio 0.08). This result is rather surprising since ketorolac 
is also highly protein-bound (99.66%) in plasma, and binding presumably also 
occurs in the CSF. This finding cannot be compared with results in a previous 
study, since unbound ketorolac concentrations were not measured in plasma 
by Rice and coworkers (1993). Moreover, to the best of my knowledge there 
are no reports on ketorolac transport by efflux or influx proteins that might 
facilitate ketorolac clearance from the CNS. Therefore, it remains unclear why 
ketorolac CNS bioavailability is less than that of other NSAIDs. 
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Diclofenac 
 
Diclofenac concentrations in the CSF were two times higher than its free 
plasma concentrations in samples collected later than 20 minutes after drug 
administration (median 1.2 and 0.8 µg/l, respectively). The binding models 
give 56-89% (Honoré and Brodersen 1984, Borgå and Borgå 1997, Yamasaki et 
al. 2000) protein binding in the CSF. Binding of 65% would be consistent with 
a CSF to free plasma ratio of 2.9, which is close to the observed median of 2.2 
in the present study. 
 
Paracetamol 
 
In study V, non-protein-bound paracetamol concentrations in plasma were 
not measured, because paracetamol is less than 20% bound to erythrocytes 
and plasma proteins at therapeutic concentrations (Milligan et al. 1994). In the 
present study, paracetamol concentrations in the CSF reached the level of 
plasma concentrations at 1 hour and remained at the same level as plasma 
concentrations thereafter. Clearly distinct CNS bioavailability is seen with 
paracetamol, when compared with NSAIDs. The difference in permeation is 
probably due to the low binding of paracetamol in blood (Parepally 2005). 
 
 
In summary, the results of indomethacin, ibuprofen, diclofenac and 
paracetamol support the theory of the equilibrium of free concentrations in 
plasma and the CSF. The calculations on protein binding suggest moderate 
protein binding in the CSF for indomethacin (40%), ibuprofen (50%) and 
diclofenac (65%). There are no studies available to base calculations on 
ketorolac and paracetamol protein binding in the CSF.  
 
The results on ketorolac conflict with the theory of the equilibrium of free 
concentrations in plasma and the CSF; in this study, ketorolac concentrations 
in the CSF were 10 times lower than its free plasma concentrations. This 
finding may explain the high incidence of systemic adverse effects of 
ketorolac. When the drug is assumed to inhibit COX in the CNS, it clearly 
inhibits COX in the kidneys and in the gastric wall, as free concentrations in 
plasma are ten-fold higher.  
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6.5 PHYSICOCHEMICAL CHARACTERISTICS OF NSAIDS AND THEIR 
CONCENTRATIONS IN THE CSF 
 
The physicochemical characteristics have a major effect on drug permeation 
through biological barriers (Davson and Segal 1996). In general, NSAIDs are 
considered to permeate through the barriers easily. The present study 
suggests that ketorolac permeates the CSF less readily than the other studied 
NSAIDs. With the lowest pKa dissociation constant, ketorolac is the most 
ionized drug in plasma pH (Table 8). This could be one explanation for the 
lower permeation, because it is believed that only the unionized drug in 
plasma can diffuse through biological barriers. 
 
Lipophilicity is another factor which may account for the lower CSF 
concentrations of ketorolac. In animals, drugs with logP values between 2.6 
and 4.3 entered the CSF easily (Péhourcq et al. 2004). The logP values of 
indomethacin, ibuprofen and diclofenac are in the upper range (4.3, 3.5, and 
4.4, respectively). In contrast, the logP value of ketorolac is in the lower range 
(2.7). Therefore, it is possible that ketorolac diffuses in the CSF to a smaller 
degree because of its lower lipophilicity. 
 
 
6.6 AGE- AND SIZE-RELATED DIFFERENCES IN DRUG 
CONCENTRATIONS IN THE CSF 
 
The present study indicates that there might be age-related differences in the 
CSF permeation of NSAIDs in children. In the present study, younger children 
had higher drug concentrations in the CSF after indomethacin and diclofenac 
than did older children. Age, height and weight were not correlated with 
ibuprofen and paracetamol CSF concentrations. 
 
Indomethacin 
 
There was a relationship between CSF indomethacin concentrations and the 
age, height, weight and body surface area of the children. Previously CSF 
indomethacin concentrations have been studied in 52 adults (Bannwarth et al. 
1990). The highest concentrations in the CSF in children and adults are 
comparable, when differences in the body weight-based doses are taken into 
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account. The lag time to reach the peak CSF concentration in adults probably 
reflects the lag in absorption after intramuscular administration and also 
slower CSF permeation, as teq usually scales with weight0.25 (Anderson and 
Meakin, 2002). Indomethacin might permeate the CSF faster in smaller 
children than in heavier children and adults. 
 
Ibuprofen 
 
The children’s weight and age were not related to ibuprofen concentrations in 
the CSF. Previously, ibuprofen concentrations in the CSF have been studied in 
46 adult patients (Bannwarth et al. 1995). The maximal observed 
concentrations in the CSF were similar in adults and children after a similar 
mean weight-adjusted dose of ibuprofen. The peak concentration was reached 
later in adults, probably because of the lag of absorption after oral dosing and 
slower permeation. 
 
Diclofenac 
 
Diclofenac concentrations in the CSF have been previously measured in only 
two adult patients (Zecca et al. 1991). In those adults, diclofenac CSF 
concentrations were similar to those observed in children in the present study. 
In the present study, smaller children had higher diclofenac concentrations in 
the CSF than did heavier children. It seems that CSF permeation is faster in 
smaller children than in heavier children and adults.  
 
Ketorolac 
 
Regression analysis to evaluate the effect of age, height, weight and body 
surface area on the CSF concentrations of ketorolac was unsuccessful. When 
comparing the results of the present study and the previous study, ketorolac 
concentrations in the CSF were four times lower in children than in adults 
(Rice et al. 1993), probably because of the 2.4-times higher im weight-based 
dose in adults. The higher volume of distribution in children (Forrest et al. 
1997, Hamunen et al. 1999) may also account for the difference. Moreover, CSF 
to total plasma concentration ratio was similar in children and adults, and 
therefore it seems that there are no major differences in the CSF ketorolac 
concentrations between children and adults. However, based on the theory of 
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faster CNS distribution of drugs in smaller children than heavier children 
(Anderson and Meakin, 2002), it is possible that ketorolac also permeates 
faster into and out of CSF in smaller children than in heavier children and 
adults.  
 
Paracetamol 
 
Based on previous reports, it seems that paracetamol permeates the CSF more 
rapidly in younger children with lower body weight than in older children 
with higher weight. Previously, a shorter CSF equilibration half-time was 
found in children with head traumas (0.7 h) (Anderson et al. 1998) than in 
adults (2.1 h) (Bannwarth et al. 1992). However, the children in Anderson’s 
study had disrupted BBB function because of brain injury. In a larger study in 
children without BBB disruption, it seemed that size rather than age explains 
the shorter CSF equilibration half-time (van der Marel et al. 2003a), and 70-kg 
standardized teq (1.9 h) was similar to that calculated from the adult data (2.1 
h) (Bannwarth et al. 1992). The results of the present study are at variance with 
those of the previous studies, since no size- or age-related difference was 
found in paracetamol concentrations in the CSF in the present study in 32 
children aged 3 months to 12 years weighing 7-69 kg. However, in the present 
study, modelling and teq calculation was not performed, and it is possible that 
differences in permeation times may not have been detected. In a previous 
study by Kozer et al. (2007), no age difference was found, because of the 
variable dose and small age range (1 week – 9 months). 
 
The CSF concentrations after paracetamol administration were higher in 
children than in adults. After the administration of the prodrug propacetamol 
in adults, paracetamol concentrations in the CSF were maximally 9 mg/l 
(Bannwarth et al. 1992), whereas that level was clearly exceeded in the present 
study (highest 18 mg/l, median 7.2 mg/l) and in the previous studies in 
children after rectal and oral dosing (van der Marel et al. 2003a, Kozer et al. 
2007). However, the ratios of paracetamol concentrations in the CSF and in 
plasma were similar in adults (Bannwarth et al. 1992) and in children (the 
present study) (Figure 21). Nevertheless, there is some indication of a 
difference between adults and children: children may have higher CSF to 
plasma ratios during 60-120 minutes (Figure 21), in agreement with shorter teq 
in children (Figure 22). Paracetamol dosing was similar in these studies. In the 
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present study, intravenous paracetamol was used, and in the adult study 
(Bannwarth et al 1992), paracetamol was administered as prodrug 
propacetamol, which is rapidly and completely hydrolyzed to paracetamol in 
plasma within 20 minutes (Granry et al. 1997). Moreover, in the present study 
in children the dose was 15 mg/kg and in the previous study in adults 2 g 
propacetamol corresponding mean paracetamol 13.9 mg/kg. The doses per 
kilogram were similar, although the per-kilogram model is not ideal 
(Anderson and Meakin, 2002). These paracetamol doses resulted in different 
plasma concentrations, which could account for the difference in the level of 
CSF concentrations. In the adult study, paracetamol concentrations in plasma 
were markedly lower (mean 8.2 mg/l at 1 hour) than in the present study 
(mean 15.5 mg/l at 1 hour). Furthermore, similar CSF to plasma paracetamol 
ratios support this theory. However, since pharmacokinetic modeling and teq 
calculation was not performed in the present study, differences in teq between 
adults (Bannwarth et al 1992) and children (present study) are not confirmed. 
It seems that paracetamol permeates the CSF faster in small children than in 
bigger children and adults, but the clinical significance and implications of 
this remains unclear. 
 
 
In summary, this study indicates that infants and small children may have 
higher CSF concentrations of NSAIDs than bigger children. This difference 
can be explained with an allometric ¼ power model, which suggests that CSF 
equilibrium half-life scales with weight0.25 (Anderson and Meakin, 2002). It is 
possible that immaturity of BCSFB function (Saunders et al. 1999), increased 
cerebral blood flow (Zwienenberg and Muizelaar, 1999), lower albumin 
content of plasma (Gomez et al. 1984), higher albumin content of the CSF 
(Biou et al. 2000, Wong et al. 2000) or other differences in drug kinetics have 
effects in the observed higher NSAID concentrations in the CSF in infants. 
However, this study was not designed to study the effect of age on drug 
concentrations in the CSF, so the sampling times were unevenly distributed in 
different age groups and the used statistical methods have some limitations. 
Therefore, the results of the present study should be considered preliminary. 
Moreover, in the present study paracetamol CSF kinetics was not correlated 
with age. Based on previous studies, size-dependent difference in paracetamol 
CSF kinetics are likely, but these size-related differences in CNS-kinetics of 
NSAIDs and paracetamol have not affected clinical practice. 
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Figure 21. Paracetamol concentration ratios CSF to plasma in adults 
(Bannwarth et al. 1992) and in children in the present study (Kumpulainen et 
al. 2007, V). Grey circles represent concentration ratios of individual patients 
in the present study, and black squares represent ratios of mean CSF and 
mean plasma concentrations in Bannwarth et al. (1992). 
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Figure 22. Simulation of paracetamol concentrations in the CSF after 
intravenous administration, with three different equilibration half-times (teq), 
measured in hours. The shorter teq results in an earlier and higher peak 
concentration in the CSF for the same dose.  
 
The simulation is for a child weighing 20 kg, after a 15-min intravenous 
infusion of paracetamol 15 mg/kg. The model was a two-compartment model 
(including central V1 and peripheral V2 compartments), with an additional 
CSF V3 compartment. The differential equations were: 
 
 
 
where A1 is the amount of paracetamol in the central compartment, A2 is the 
amount in the peripheral compartment, A3 is the amount in the CSF…  
(Continues on the next page)  
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(Figure 22) 
… Q2 is the intercompartmental clearance between the central and peripheral 
compartments, CL is the clearance from the central compartment, C1 is the 
concentration of paracetamol in the central compartment, C2 is the 
concentration in the peripheral compartment, C3 is the concentration in the 
CSF compartment, Keq is the equilibration rate constant between the central 
and the CSF compartments. Partition coefficient was assumed 1. For 
parameter values see Anderson et al. (2005). 
 
 
 
6.7 SEX DIFFERENCE IN DRUG CONCENTRATION IN THE CSF 
 
Previous reports indicate that there may be gender or sex differences in 
response to analgesics (Ciccone and Holdcroft 1999, Greenspan et al. 2007). An 
association of sex and drug concentrations in the CNS has not been reported 
earlier. In this study, girls had higher paracetamol concentrations in the CSF 
than boys. However, the study was not powered and designed to study sex 
difference of drug concentrations in the CSF: the sample size was small and 
sampling times were unevenly distributed between girls and boys. In 
previous studies in children (Anderson et al. 1998, van der Marel et al. 2003a, 
Kozer et al. 2007), no sex difference in paracetamol concentrations in the CSF 
was found. Therefore, it seems that there are no true differences in CNS 
pharmacokinetics between boys and girls. 
 
Some previous studies indicate that minor differences in paracetamol 
pharmacokinetics in women may occur in connection with the menstruation 
cycle (Wójcicki et al. 1979, Gugilla et al. 2002). Furthermore, female infants up 
to three months of age have been shown to have higher estradiol levels than 
older children (Chada et al. 2003) or males (Schmidt et al. 2002), which might 
also suggest a sex difference in paracetamol kinetics. However, most previous 
studies on paracetamol pharmacokinetics (Forrest et al. 1982, Anderson et al. 
1998, 2004, 2005, van der Marel et al. 2003b, Jacqz-Aigrain and Anderson 2006, 
Duggan and Scott 2009) suggest that no sex difference in pharmacokinetics 
occur. 
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6.8 PROTEIN BINDING IN PLASMA 
 
In the present study, NSAIDs were highly bound to proteins in plasma. 
Indomethacin was 99.96%, ibuprofen 99.80%, ketorolac 99.66% and diclofenac 
99.90% bound to proteins. The results are similar to previous findings, where 
protein binding was also high: indomethacin >99.7% (Bannwarth et al. 1990), 
ibuprofen >99% (Davies 1998), ketorolac >99% (Gillis and Brogden 1997) and 
diclofenac >99.7% (Davies and Anderson 1997). As discussed previously, 
protein binding in plasma is a major factor affecting NSAID CNS permeation. 
In the present study, the children were healthy, undergoing elective surgery 
and presumably had normal plasma albumin concentrations. However, in 
children suffering from malnutrition, and even in those with an acute illness, 
plasma albumin concentrations decrease (Potter and Luxton 1999). This leads 
to decreased NSAID binding and increased unbound drug concentration, and 
consequently increased diffusion to the CNS.  
 
 
6.9 ANALGESIC CONCENTRATIONS IN PLASMA 
 
Pain occurrence after inguinal surgery was closely monitored in three (II) and 
eight (IV) children to get a plasma sample at onset of pain. The children had 
spinal anaesthesia with standard weight-based doses of levobupivacaine, light 
sedation for the operation and preoperatively one dose of ibuprofen or 
diclofenac. However, these results should be considered preliminary. No 
conclusions based on the results can be drawn, since the sample size was too 
small and the timelines of different events affecting the time course of pain 
(drug administration, spinal anaesthesia, sedation, the beginning and the end 
of operation) were variable. Nevertheless, it seems that pain occurrence after 
spinal anaesthesia varies, and therefore pain medication should be 
administered preventively and based on individual needs.  
 
 
6.10 THE ADVERSE EFFECTS 
 
A total of 41 adverse effects were reported in 40 out of 160 children, but no 
serious or unexpected adverse effects were noted. Because the study design 
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was open, the observations may have bias. Moreover, no follow-up for 
adverse effects after discharge was arranged.  
 
CNS adverse effects (agitation and anxiety) occurred in 19 children (12%) in 
the PACU. Emergence agitation is a common adverse effect after inhalation 
anaesthesia with sevoflurane (Goa et al. 1999, Kuratani and Oi 2008), and 
restlessness has also been reported after spinal anaesthesia, with an incidence 
of 7% (Kokki and Hendolin 1996). NSAIDs, especially indomethacin, may 
cause CNS adverse effects, headache, dizziness, anxiety, agitation and 
cognitive dysfunction (Tharumaratnam et al. 2000, Clunie et al. 2003). In this 
study, 5/31 children who had received indomethacin and 7/30 children who 
had received ketorolac experienced CNS adverse effects. Because anaesthesia 
and sedation was standardized, the CNS adverse effects may be connected to 
the study drugs.  
 
Gastrointestinal adverse events (vomiting 5%, nausea 4%, abdominal pain 1%) 
occurred at similar incidences as reported in a previous study in children with 
spinal anaesthesia (Kokki and Hendolin 1996), and may be related to the 
study drugs. Urticaria occurred in one child after the child had received 
intravenous ketorolac and a concomitant buccal midazolam-ketamine 
premedication, and may be related to ketorolac. Shivering was recorded in 
four children (2.5%), at a similar incidence as reported by Kokki and Hendolin 
(1996). Shivering is common after spinal anaesthesia in children (Kokki and 
Hendolin 1996, Crowley and Buggy 2008), and was probably not related to the 
study medications.  
 
 
6.11 FUTURE PERSPECTIVES 
 
In the present study, concentrations of NSAIDs and paracetamol were studied 
after a single intravenous dose. In the future it would be interesting to build a 
population pharmacokinetic model using the data of the present study. With 
the model it would be possible to evaluate the effect of size on CSF 
equilibrium half-life and to simulate CNS concentrations after repeated doses 
and continuous infusion. Moreover, a further study of the CNS kinetics of 
ketoprofen is warranted, since Mannila et al. (2006) sampled the CSF only up 
to 67 minutes, with increasing ketoprofen concentrations. It would be useful to 
97 
find out whether the peak in the CSF occurs at 1 hour or later after 
intravenous ketoprofen, and to gain more knowledge of the elimination of 
ketoprofen from the CSF. Furthermore, the concentrations of non-opioid 
analgesics in the tissues of the CNS should be investigated, using 
microdialysis methods, for example. However, the value of future clinical 
trials on CNS kinetics is controversial; it is hard to see how such studies would 
change clinical practice or fundamental concepts of the use of the drugs. On 
the other hand, pharmacodynamic trials studying the relationship of CNS 
kinetics and analgesia would be difficult to conduct, but could improve 
clinical practice. Moreover, when paediatric CNS bioavailability is considered, 
it seems that CSF equilibrium half-life (teq) is related to size, but other 
differences are small, and therefore the justification of paediatric clinical trials 
on CNS kinetics is questionable.  
 
The findings of the present study do, however, support the concept of 
preemptive analgesia. There may be delays in the onset of analgesia after oral 
administration, partly due, to the time needed for absorption from the gut into 
the plasma. This thesis also documents CSF delays after intravenous 
administration due to the delay between plasma and CSF. CSF is mooted to be 
the site of action of both NSAIDs and paracetamol. These drugs should be 
given intravenously about 30 min before the onset of pain (e.g., 30 min before 
arriving in the recovery room after a surgical procedure). The delay between 
administration and effect is greater after oral administration, and this affects 
the timing of oral doses that are best given before the surgical procedure.
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7 Summary and conclusions 
NSAIDs and paracetamol have an analgesic effect in the CNS mediated 
through prostaglandin H2 synthetase (PGHS) enzyme inhibition. However, 
the CSF distribution of these analgesics in healthy children has not been 
previously studied. NSAIDs are highly protein bound to albumin (>99%). 
Concentrations of indomethacin, ibuprofen, ketorolac, diclofenac and 
paracetamol in the CSF were studied in 160 children. CSF was sampled during 
spinal anaesthesia 5 min–22 h after intravenous analgesic injection. The 
following conclusions can be made: 
 All the investigated drugs exhibited permeability of the BBB and 
were detectable within the CSF during the study period, consistent 
with their centrally mediated mechanism of action. 
 The highest concentrations of ibuprofen, ketorolac, diclofenac and 
paracetamol in the CSF occurred within one hour after 
intravenous administration. CSF concentrations of indomethacin 
were higher than unbound plasma concentrations over the study 
period, suggesting rapid distribution to the CSF (peak <30 min).  
 Total CSF/unbound plasma concentrations were greater than unity 
for indomethacin, ibuprofen and diclofenac, consistent with the 
theory of equilibrium between unbound concentration in plasma 
and the CSF. CSF proteins, albeit less than plasma, contribute to 
binding in the CSF (approx. 15-69%) and cause higher total CSF 
drug concentration. 
 CSF/unbound plasma ketorolac concentration ratios were below 
one; the reason for this may be ionization, less lipophilicity or 
active transport.  
100 
 
 Paracetamol concentrations in the CSF are similar to those in 
plasma after one hour, consistent with its low degree of binding in 
blood (<50%). 
 Age-related differences in NSAID or paracetamol CNS 
bioavailability were not detectable with the current study protocol.  
Concentrations of NSAIDs in CSF are likely to have a closer temporal 
relationship with analgesia than those in plasma. The time of analgesic 
delivery should be tailored so that peak CSF concentrations precede the onset 
of maximum pain, e.g. emergence from anaesthesia where a regional block is 
not used. Further clinical studies are required to confirm this hypothesis. 
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Non-steroidal anti-inflammatory drugs 
and paracetamol are commonly used 
analgesics in acute pain management. In 
the present study the permeation of these 
drugs into the central nervous system 
was evaluated in 160 healthy children.  
Diclofenac, ibuprofen, indomethacin and 
ketorolac permeated the cerebrospinal 
fluid readily and reached the highest 
concentrations one hour after intravenous 
dosing. However, the concentrations were 
100-fold lower when compared to that in 
plasma. Paracetamol performed different-
ly: the cerebrospinal fluid concentrations 
reached the level of plasma concentrations 
at one hour.  These results suggest that the 
optimal timing for intravenous adminis-
tration of non-opioid analgesics is an hour 
before the onset of acute pain.
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